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1. Introduction 
Like all other organs and tissues in a mammalian body, the heart muscle requires oxygen-
rich blood in order to function, while oxygen-depleted blood needs to be transported away 
from organs. The first requirement is accomplished through the coronary artery networks 
which serve to furnish blood supply to the cardiac muscle, while the second is attained 
through a network of blood veins. 
 
Fig. 1. The coronary artery network of the heart. 
www.intechopen.com
 
Coronary Artery Disease – New Insights and Novel Approaches 
 
4 
The coronary artery system consists of two main arteries, the left and right arteries, and 
their marginal arterial network. Anatomically, the left main coronary artery (LMCA) 
consists of the left anterior descending artery and the circumflex branch that supplies 
blood to the left ventricle and atrium (Figure 1). Additional arteries branching off the 
LMCA furnish the left heart side muscles with blood. These include the circumvent 
artery, which branches off the left coronary artery and encircles the muscle to supply 
blood to the lateral side and back of the heart, and the left anterior descending artery, 
which supplies the blood to the front of the left side of the heart. The right coronary 
artery, on the other hand, branches into the right posterior descending and acute marginal 
arteries to supply blood to the right ventricle, right atrium sinoatrial node (cluster of cells 
in the right atrial wall that regulate the heart’s rhythmic rate) and the atrioventricular 
node. Other smaller branches of the coronary arteries include the acute marginal, 
posterior descending, obtuse marginal, septal perforator and the diagonals, which 
provide the surrounding network with blood supply.  
2. What causes coronary artery disease?  
Since coronary arteries deliver blood to the heart muscle, disease can have serious 
implications by reducing the flow of oxygen and nutrients to the heart, which in turn may 
lead to a heart attack and possibly death. Besides, the susceptibility and function of  
the vessel wall are dependent on the balance of several counteracting forces, i.e., 
vasoconstricting versus vasodilating, growth-promoting versus growth-inhibiting and 
proapoptotic versus antiapoptotic functions. While these factors are tightly balanced in a 
normal healthy vessel, under pathophysiologic conditions this balance is upset resulting in 
the development of vascular hypertrophy and the generation of proatherogenic vascular 
lesions, thereby triggering the initiation and progression of coronary artery disease (CAD) 
or atherosclerosis (as it is often called). CAD is a complex disorder, which culminates in the 
coronary bed system failing to furnish adequate blood supply to the heart. The disease has 
no clear etiology and manifests itself both in the young (early onset) as in familial cases as 
well as in adults (late onset).  
One major culprit for CAD is a perturbation in lipid metabolism. A lipid is any fatty 
material or fat-like substance, e.g. normal body fat, cholesterol (i.e. high density and low 
density lipoproteins), other steroids, and substances containing fats, such as 
phospholipids, glycolipids and lipoproteins. Specifically, cholesterol (Chol) constitutes 
one of the most clinically important lipid substances, and alterations in the balance 
between its synthesis and the metabolism of its by-products is a major source of 
cardiovascular complications. Together with its metabolites, Chol plays a variety of 
essential roles in living systems. In fact, virtually all animal cells require Chol, which they 
acquire through synthesis or uptake, but only the liver can degrade it. Failure of metabolic 
pathways to break these substances down as required, or by the system to maintain the 
right balance, will lead to their increased levels, and therefore predispose an individual to 
acquiring CAD. Circulating lipoproteins are regulated at various levels, ranging from 
Chol synthesis, transport and metabolism. Chol biosynthesis comprises the condensation 
of acetyl-CoA and acetoacetyl-CoA into 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA), which in turn is reduced to mevalonate by the HMG-CoA reductase (HMGCR) 
followed by oxidoreduction and decarboxylation intermediate steps leading to the 
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conversion of lanosterol to Chol. It is regulated through feedback inhibition by sterols and 
non-sterol metabolites derived from mevalonate. The HMGCR, an integral glycoprotein of 
endoplasmic reticulum membranes that remains in the endoplasmic reticulum after 
synthesis and glycosylation, is the rate-limiting enzyme in Chol biosynthesis in 
vertebrates.  
The maintenance of Chol homeostasis encompasses diverse metabolic pathways linked to 
its transportation, metabolism and its metabolic by-products. Since Chol is insoluble in 
blood, it is transported in the circulatory system within a large range of lipoproteins in 
blood. Thereby, its transportation to peripheral tissues is accomplished by the 
lipoproteins, chylomicrons, very low density lipoproteins (VLDLs) and low density 
lipoproteins (LDLs), while high-density lipoprotein (HDL) particles transport it back to 
the liver for excretion. Functionally, LDL is a metabolic end-product of the triglyceride 
(TG)-rich lipoproteins (i.e. VDLDs). Lipoprotein metabolism constitutes a major 
component in the regulation of Chol homeostasis. Systems regulating Chol levels include 
the LDL receptor (LDLR) pathway and its ligand the apolipoprotein B100 (Apo B), which 
are involved in the maintenance of its homeostasis in the body by regulating the hepatic 
catabolism of LDL-Cholesterol (LDL-C), and the proprotein convertase subtilisin/kexin 
type 9 (PCSK9). The serine protease PCSK9 is a member of the proteinase K subfamily of 
subtilases that also affects plasma LDL-C levels by altering LDLR levels via a post-
transcriptional mechanism1, and cellular Chol metabolism by regulating both LDLR and 
circulating Apo B-containing lipoprotein levels in LDLR-dependent and -independent 
fashions2-4. It regulates LDL-C levels apparently both intracellularly and by behaving as a 
secreted protein that can be internalized by binding the LDLR. In the liver, it controls the 
plasma LDL-C level by post-transcriptionally downregulating the LDLR through binding 
to the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR5, 
independently of its catalytic activity. The LDLR regulates the plasma LDL-C 
concentration by internalizing Apo B and Apo E-containing lipoproteins via receptor-
mediated endocytosis. Apo B is a large, amphipathic glycoprotein that plays a central role 
in human lipoprotein metabolism. Two forms of Apo B are produced from the Apo B gene 
through a unique posttranscriptional editing process: Apo B-48, which is required for 
chylomicron production in the small intestine, and Apo B required for VLDL production 
in the liver. In addition to being the essential structural component of VLDL, Apo B is the 
ligand for LDLR-mediated endocytosis of LDL particles. Lipoprotein (a) [Lp(a)] contains 
an LDL-like moiety, in which the Apo B component is covalently linked to the unique 
glycoprotein apolipoprotein(a) (Apo A). Apo A-I is essential for the formation of HDL 
particles. Apo A-I-containing HDL particles play a primary role in Chol efflux from 
membranes, at least partly, through interactions with the adenosine triphosphate-binding 
cassette transporter A1 (ABCA1). The ABCA1 regulates the rate-controlling step in the 
removal of cellular Chol, i.e. the efflux of cellular Chol and phospholipids to an 
apolipoprotein acceptor. Apo A is composed of repeated loop-shaped units called 
kringles, the sequences of which are highly similar to a kringle motif present in the 
fibrinolytic proenzyme plasminogen. Variability in the number of repeated kringle units 
in the Apo A molecule gives rise to different-sized Lp(a) isoforms in the population. 
Based on the similarity of Lp(a) to both LDL and plasminogen, its function is thought to 
represent a link between atherosclerosis and thrombosis. However, determination of the 
function of Lp(a) in vivo remains elusive. Mechanistically, elevated Lp(a) levels may 
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either induce a prothrombotic/anti-fibrinolytic effect as Apo A resembles both 
plasminogen and plasmin but has no fibrinolytic activity, and/or may accelerate 
atherosclerosis because, like LDL, the Lp(a) particle is Chol-rich. Apolipoprotein E (apo E) 
is also a constituent of various lipoproteins and plays an important role in the transport of 
Chol and other lipids among cells of various tissues.  
Apart from lipoproteins, circulating VLDLs serve as vehicles for transporting lipids to 
peripheral tissues for energy homeostasis. VLDLs are TG-rich particles synthesized in 
hepatocytes and secreted from the liver in a pathway that is tightly regulated by insulin. 
Hepatic VLDL production is stimulated in response to reduced insulin action, resulting in 
increased release of VLDL into the blood under fasting conditions, while it is suppressed in 
response to increased insulin release after meals. This effect is critical for preventing 
prolonged excursion of postprandial plasma lipid profiles in normal individuals. HDL 
particles are key players in the reverse Chol transport by shuttling it from peripheral cells 
(e.g. macrophages) to the liver or other tissues. This complex process is thought to represent 
the basis for the antiatherogenic properties of HDL particles. Accordingly, the particles 
mediate the uptake of peripheral Chol and return it to the liver for bile acid secretion 
through exchange of core lipids with other lipoproteins or selective uptake by specific 
receptors. These particles vary in size and density, mainly because of differences in the 
number of apolipoprotein (apo) particles and the amount of Chol ester in the core of HDL 
molecule.  
The majority of lipoprotein disorders result from a combination of polygenic 
predisposition and poor lifestyle habits, including physical inactivity, increased visceral 
adipose tissue, increased caloric intake, and cigarette smoking. Plasma elevation of LDL-
C, VLDL and Lp(a), as well as reduced HDL-C levels are predisposing factors for CAD. 
The amount of Chol transported is inversely correlated with the risk for CAD. Reduced 
circulating levels of HDL-C are a frequent lipoprotein disorder in CAD patients and can 
be caused by either genetic and/or environmental factors (sedentary lifestyle, diabetes 
mellitus, smoking, obesity or a diet enriched in carbohydrates. Lp(a) is a unique 
lipoprotein particle consisting of a moiety identical to LDL to which the glycoprotein 
Apo(a) that is homologous to plasminogen is covalently attached. These features  
have suggested that Lp(a) may contribute to both proatherogenic and 
prothrombotic/antifibrinolytic processes, which constitute a risk factor for premature 
cardiovascular disease. Among others, the association between elevated Lp(a) levels and 
increased CAD risk, indicates that elevated Lp(a), like elevated LDL-C, is causally related 
to premature CAD. However, although Lp(a) has been shown to accumulate in 
atherosclerotic lesions, its contribution to the development of atheromas is unclear. This 
uncertainty is related in part to the structural complexity of the Apo A component of 
Lp(a) (particularly apo A isoform size heterogeneity), which also poses a challenge for 
standardization of the measurement of Lp(a) in plasma. However, while LDL and Lp(a) 
are now believed to be atherogenic, the role of VLDL as an independent risk factor 
remains controversial. On the other hand, the HDL is the only lipoprotein that has been 
established as antiatherogenic, thought to reduce CAD risk by mediating Chol efflux from 
the periphery by way of transportation to the liver for excretion.  
Hepatic lipase (HL), a member of the lipase superfamily, is a lipolytic enzyme that is 
produced primarily by hepatocytes, where it is secreted and bound to the hepatocyte 
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surface and readily released by heparin. It is homologous to LPL and pancreatic lipase 
and hydrolyzes TGs and phospholipids in all lipoproteins, but is predominant in the 
conversion of IDL to LDL and the conversion of post-prandial TG-rich HDL into the post 
absorptive TG-poor HDL. Thus, the enzyme contributes to the regulation of plasma TG 
levels by facilitating its exudation from the VLDL pool, in a fashion that is governed by 
the composition and quality of HDL particles. It is thought that HL directly couples HDL 
lipid metabolism to tissue/cellular lipid metabolism43. Accordingly, hepatic lipase HDL 
regulates the release of HL from the liver and HDL, controls HL transport and activation 
in the circulation in a fashion that is regulated by factors that release it from the liver and 
activate it in the bloodstream. Therefore, alterations in HDL-apolipoprotein composition 
can disturb HL function by inhibiting the release and activation of the enzyme, thereby 
affecting plasma TG levels and CAD risk. It has been suggested that the HL pathway 
potentially provides the hepatocyte with a mechanism for the uptake of a subset of 
phospholipids enriched in unsaturated fatty acids and may allow the uptake of 
cholesteryl ester, free Chol, and phospholipid without catabolism of HDL 
apolipoproteins43. HL plays a secondary role in the clearance of chylomicron remnants by 
the liver43. Consistent with IDL being a substrate for HL, the human post-heparin HL 
activity is inversely correlated with IDL-C concentration only in subjects with a 
hyperlipidaemia involving VLDL. HDL-C has been reported to be inversely correlated to 
HL activity, leading to the suggestion that lowering HL would increase its levels. 
Common hormonal factors, such as estrogen, have also been shown to upregulate Apo A 
and HDL-C and lower HL. Hence this relationship may not be specific. However, an 
increase in HDL-C, Apo A, or HDL –triglycerides has been observed in severe deficiency 
of HL. Apart from heparin, HL also binds o the LDLR-related protein. This has led to the 
notion that enzymatically inactive HL may play a role in hepatic lipoprotein uptake, 
forming a bridge by binding to the lipoprotein and to the cell surface, raising the 
possibility that production and secretion of mutant inactive HL could promote clearance 
of VLDL remnants.  
One of the important proteins involved in lipoprotein metabolism is the CETP. Plasma 
CETP facilitates the transfer of cholesteryl ester from HDL to Apo B-containing lipoproteins 
by catalyzing the transfer of insoluble esters in the reverse transport of Chol. Thus, CETP is 
involved in maintaining the balance between the LDL-C, ("bad" Chol) and HDL-C ("good" 
Chol), which is a risk factor for hyperlipidaemia. Since CETP regulates the plasma levels of 
HDL-C and the size of HDL particles, it is considered to be a key protein in reverse Chol 
transport, a protective system against atherosclerosis. In mediating the transfer of 
cholesteryl esters from antiatherogenic HDL to proatherogenic apolipoprotein apo-B-
containing lipoprotein particles (including VLDL, VLDL remnants, IDL, and LDL), the 
CETP plays a critical role not only in the RCT pathway but also in the intravascular 
remodeling and recycling of HDL particles6,7.  
In mammalian cells, Chol homeostasis is controlled primarily by regulated cleavage of 
membrane-bound transcription factors, the sterol regulatory element binding proteins 
(SREBPs)8-10 and their cleavage-activating protein (SCAP)11,12. The SREBPs activate specific 
genes involved in Chol synthesis, LDL endocytosis, fatty acid synthesis and glucose 
metabolism, providing a link between lipid and carbohydrate metabolism13. All three 
SREBP isoforms SREBP-1a, SREBP-1c and SREBP-2 (encoded by two genes) that are 
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synthesized as 125 kDa precursor proteins localized to the endoplasmic reticulum14, and 
play a central role in energy homeostasis by promoting glycolysis, lipogenesis and 
adipogenesis15-19. Functionally, SREBP-2 gene activation leads to enhanced Chol uptake and 
biosynthesis, while SREBP-1 is primarily involved in fatty acid and glucose metabolism20-22. 
Mechanistically, it is thought that when cells are deprived of Chol, SREBPs are cleaved by 
two proteolytic steps. First, the SREBP precursor is transported to the Golgi by the 
chaperone protein SCAP and cleaved via two proteases to release the mature, 
transcriptionally active 68 kDa amino terminal domain11,12. This domain is then released 
from the endoplasmic reticulum membrane and transported into the nucleus, where it binds 
to specific nucleotide sequences in the promoters of the LDLR and other genes regulating 
Chol and TG homeostasis10.  
While disorders of Chol metabolism and related lipoproteins occupy a pivotal position in 
events leading to CAD, other important contributors include those that regulate the 
viability of blood vessels affecting vascular function leading to the formation of plaques. 
This is particularly true for coronary arteries, for example, in which an imbalance in a 
number of these processes triggers a proatherogenic state initiating the progression of 
atherosclerosis. Several disease pathways associated with regulation of blood pressure 
and glucose metabolism are involved in intricate ways. The metabolic syndrome poses a 
major public health problem by predisposing individuals to CAD and stroke, the leading 
causes of mortality in developed countries. Its impact on the risk of atherosclerotic 
cardiovascular disease is greater than that of any of its individual components. 
Frequently, many of these metabolic manifestations, precede the development of overt 
diabetes by many years23. This syndrome is manifest clinically by such cardiovascular risk 
factors as hypertension, dyslipidaemic, and coagulation abnormalities. This abnormal 
metabolic milieu contributes to the high prevalence of macrovascular complications 
including CAD as well as more generalized atherosclerosis. It is frequently seen in obese 
individuals, and characterized by glucose intolerance, hyperinsulinemia, a characteristic 
dyslipidaemic (high TGs; low HDL-C, and small, dense LDL-C), obesity, upper-body fat 
distribution, hypertension, increased prothrombotic and antifibrinolytic factors, and 
therefore an increased risk of CAD23. However, while the conventional risk factors, 
insulin resistance parameters, and metabolic syndrome are important in predicting CAD 
risk, in some population environmental factors may be determinant in the ultimate 
manifestation of the disease.  
Apart from the PPARs, the Forkhead transcription factor (Foxo1) is also believed to play an 
essential role in controlling insulin-dependent regulation of microsomal TG transfer protein 
(MTP) and apolipoprotein C-III (Apo C-III), two key components that catalyze the rate-
limiting steps in the production and clearance of triglyceride-rich lipoproteins24,25. Under 
physiological conditions, Foxo1 activity is inhibited by insulin, while under insulin resistant 
conditions Foxo1 becomes uncontrolled, contributing to its hyperactivity in the liver24. This 
effect contributes to hepatic overproduction of VLDL and impaired catabolism of 
triglyceride-rich particles, accounting for the pathogenesis of hypertriglyceridemia. Thus, 
augmented Foxo1 activity in insulin resistant livers promotes hepatic VLDL overproduction 
and predisposes to the development of hypertriglyceridemia25, offering a possible route for 
this manifestation. 
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As such the contributions of the individual disease pathways such as diabetes or 
hypertension may manifest themselves independently or in combination with other 
disorders, leading to other complications with added risk as is the case with the metabolic 
syndrome. Among these, type 2 diabetes mellitus (T2DM) constitutes probably the most 
important risk disease for CAD. In contrast to type 1 diabetes mellitus, the type 2 
endocrinopathy is clustered in minority populations and has both strong genetic and 
environmental components that influence its manifestation. This disease is a heterogeneous 
disorder and patients are often characterized by features of the insulin resistance syndrome, 
also referred to as the metabolic syndrome. This syndrome is defined as a cluster of 
interrelated common clinical disorders, including obesity, insulin resistance, glucose 
intolerance, hypertension, and dyslipidaemic (hypertriglyceridaemia and low HDL-C 
levels), exhibiting rising incidence to epidemic levels in the developed world. Among 
others, insulin has important vascular actions to stimulate production of nitric oxide from 
endothelium. This leads to capillary recruitment, vasodilatation, increased blood flow, and 
subsequent augmentation of glucose disposal in classical insulin target tissues, such as the 
skeletal muscle. Individuals displaying three of the features of insulin resistance (elevated 
plasma insulin and apolipoprotein B concentrations and small, dense LDL particles) show a 
remarkable increase in CAD risk and the increased risk associated with having small, dense 
LDL particles may be modulated to a significant extent by the presence/absence of insulin 
resistance, abdominal obesity and increased LDL particle concentration26. They influence 
risk for CAD through promoting endothelial dysfunction and enhanced production of 
procoagulants by endothelial cells27. 
Systems regulating the coagulation mechanisms also have their fair share of disease 
pathways leading to CAD. To begin with, blood platelets play a crucial role in 
physiological haemostasis and in the pathology of prothrombotic states, including 
atherosclerosis. Platelets are anucleate cells with no DNA. The differentiation of their 
precursor, the megakaryocyte, is characterized by nuclear polyploidization through a 
process called endomitosis. Changes in the megakaryocyte-platelet-haemostasis axis may 
precede acute thrombotic events. Thereby, the changes in megakaryocyte ploidy 
distribution may be associated with the production of large platelets. Large platelets are 
denser and more active haemostatically. Mean platelet volume, an important biological 
variable determinant of platelet reactivity, is increased in patients after MI and is a 
predictor of a further ischaemic event and death following MI28. Apart from platelets, 
changes also in the parental megakaryocyte are associated with chronic and acute 
vascular events29. The regulation of megakaryocytopoiesis depends on several 
haematopoietic factors such as thrombopoietin. In T2DM, platelet abnormalities, 
including altered adhesion and aggregation, render the cells hypersensitive to agonists. 
Besides, disturbed carbohydrate and lipid metabolism may lead to physicochemical 
changes in cell membrane dynamics, and consequently altered exposure of surface 
membrane receptors. These manifestations, together with increased fibrinogen binding, 
prostanoid metabolism, phosphoinositide turnover and calcium mobilization often 
present in diabetic patients, contribute to enhanced risk of small vessel occlusions and 
accelerated development of atherothrombotic disease of coronary, cerebral and other 
vessels in diabetes. The disease has emerged as an important condition of older patients in 
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which both microvascular and macrovascular complications are a common cause of 
morbidity and mortality. Microvascular complications have only been recently recognized 
as an important and frequent complication of T2DM30. 
Additionally, environmental factors, such as food consumption, constitute important 
components regulating pathways to complex diseases such as CAD and cancer. Dietary 
Chol absorption, endogenous Chol synthesis and biliary Chol excretion regulate whole body 
Chol balance as a result of biotransformation into bile acids or direct Chol excretion. Nuclear 
hormone receptors, such as the liver X, farnesoid X and retinoid X receptors, regulate the 
absorption of dietary sterols by modulating the transcription of several genes involved in 
Chol metabolism31. The ABC proteins transport dietary Chol from enterocytes back to the 
intestinal lumen, thus limiting the amount of absorbed Chol. By means of the same 
mechanism, ABC transporters also provide an efficient barrier against the absorption of 
plant sterols31, which may vary among different ethnic populations. For example, it appears 
that some ethnic groups are at higher risk than others for the development of obesity and 
obesity-related non-communicable diseases, including insulin resistance, the metabolic 
syndrome, T2DM and CAD. Put together therefore, because of the various interactive 
factors regulating the functionality of coronary vascular beds, many risk factors may 
contribute to an individual acquiring the disease.  
2.1 Coronary artery disease manifestation in the adult 
These risk factors for CAD can be classified into those that regulate the levels of circulating 
lipoproteins, and those that regulate the susceptibility of arterial walls. Factors regulating 
lipoprotein levels include high circulating Chol and saturated fats in diet, obesity and 
emotional and neurogenic factors and those that regulate arterial susceptibility are insulin 
resistance, diabetes, hypertension, smoking and age (Figure 2). All these factors contribute 
to the pathways leading to atherosclerosis, oft in combination with environmental factors. 
Apart from the fact that most of the predisposing diseases are themselves complex ailments, 
combinations of some of these disorders can cluster to induce other forms of maladies, such 
as the metabolic syndrome, which in themselves constitute an added risk for coronary 
disease. 
For almost all of these disease pathways, their impact on CAD manifestation can be 
classified as major or minor, depending on their assessed contribution (Figure 2). For 
example, in the regulation of blood pressure homeostasis insulin-resistant diabetes mellitus 
and essential hypertension are among the primary culprits, while angiotensin converting 
enzyme (ACE) and angiotensin 1 make up secondary causative factors. Furthermore, a great 
majority of these risk factors (e.g. hypertension, diabetes, hyperlipidaemia) are themselves 
complex disorders underlying a variety of etiologies. In essence therefore, CAD is shaped by 
a whole spectrum of phenotypic expression evolving through various events that lead to the 
formation and progression of atherosclerotic plaque in the inner lining of an artery causing 
it to narrow or become blocked and finally exude circulatory complications. The ultimate 
disease manifestation is an expression of the shift in the balance of interactions among 
factors influencing various aspects of coronary artery function and structure with prevalent 
genetic factors. 
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Fig. 2. The risk factors contributing to coronary artery disease pathways. The pathways may 
lead to either an increase in in circulating lipoproteins, influence susceptibility of the vessel 
walls or both components of atherosclerotic plaque formation. 
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2.1.1 Lipid metabolism and manifestation of coronary artery disease 
As stated above, defects in lipid metabolic pathways, leading to increased circulating Chol 
levels constitutes the major underlying cause of CAD. Hyperlipidaemia, also sometimes 
referred to as hyperlipoproteinemia or dyslipidaemia, is the condition in which the blood 
lipid levels are too high, often leading to various cardiovascular disorders, particularly 
CAD. These disorders exist as hypercholesterolaemia, which is characterized by increased 
LDL levels, hypertriglyceridaemia characterized by increased chylomicrons or VLDL levels 
or combined disease manifest as increased LDL and VLDL, or VLDL and chylomicrons. 
Affected individuals may also have hypercholesterolaemia or chylomicron abnormalities of 
VLDL origin, with normal LDL-C levels, which is also defined as hyperlipoproteinemia.  
Six subtypes of hyperlipoproteinemia types (I, II, III, IV, V and unclassified forms) have 
been characterized to date. Type I (also known as Buerger-Gruetz syndrome, primary 
hyperlipoproteinemia, or familial hyperchylomicronemia) is a very rare form due to a 
deficiency of lipoprotein lipase (LPL) or altered apolipoprotein C2. It results in elevated 
chylomicrons, the particles that transfer fatty acids from the digestive tract to the liver, 
exhibiting a prevalence of 0.1% of the population. Hyperlipoproteinemia type II, by far the 
most common form, is further classified into type IIa and type IIb, depending mainly on 
whether there is elevation in the TG level in addition to LDL-C. Thereby type IIa is known 
as familial hypercholesterolaemia. This form may be sporadic (due to dietary factors), 
polygenic, or truly familial as a result of a mutation either in the LDLR gene on chromosome 
19 (0.2% of the population) or the Apo B gene (0.2%). In type IIb, the high VLDL levels are 
due to overproduction of substrates, including TGs, acetyl CoA, and an increase in Apo B 
synthesis. They may also be caused by the decreased clearance of LDL, with a prevalence of 
10% in the population. These include (a) familial combined hyperlipoproteinemia (FCH) 
and (b) secondary combined hyperlipoproteinemia (usually in the context of metabolic 
syndrome, for which it is a diagnostic criterion). Hyperlipoproteinemia type III, also known 
as broad beta disease or dysbetalipoproteinemia, is due to high chylomicrons and 
intermediate density lipoprotein (IDL). It is due to the presence of elevated Chol-rich VLDL 
(ǃ-VLDL) levels showing a prevalence of 0.02% in the general population.  
The type IV form, also known as hypertriglyceridaemia (or pure hypertriglyceridaemia) is due 
to high TGs, with prevalence of 1%, while type V is very similar to type I, but with high VLDL 
in addition to chylomicrons. The rate of synthesis of TG-rich lipoproteins, LPL-mediated TG 
hydrolysis, and the hepatic capture of chylomicron remnants via the interaction of the 
lipoprotein receptor with Apo E and LPL, is key to the metabolism and modification of these 
lipoproteins. The modulation of such phenomena is influenced by both genetic and 
environmental factors, thus explaining their extraordinary individual variance32. Non-
classified forms are extremely rare. They include hypo-alpha lipoproteinemia and hypo-beta 
lipoproteinemia with a prevalence of 0.01 - 0.1%. In subjects with and T2DM, the ability of 
insulin to regulate VLDL production becomes impaired due to insulin resistance in the liver, 
resulting in excessive VLDL secretion and accumulation of TG-rich particles in the blood. Such 
abnormality in lipid metabolism characterizes the pathogenesis of hypertriglyceridaemia and 
accounts for increased risk of CAD in obesity and T2DM. Accumulating evidence also points 
to hypertriglyceridaemia as a marker for increased risk for CAD, and in fact, several 
atherogenic factors, such as increased concentrations of TG-rich lipoproteins, the atherogenic 
lipoprotein phenotype, (or lipid triad) and the metabolic syndrome33,34. The lipid triad consists 
of elevated serum TGs, small LDL particles, and HDL-C. The metabolic syndrome includes the 
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coexistence of the lipid triad, elevated blood pressure, insulin resistance (plus glucose 
intolerance), and a prothrombotic state. However, the molecular basis that links insulin 
resistance to VLDL overproduction remains poorly understood. 
Pathway Primary risk determinants Secondary risk determinants 
Lipid 
metabolism 
Familial dyslipidaemic disorders, 
including familial hypercholesterolaemia, 
familial defective apopliporptein B-100; 
Apopliporptein B-100; Sitosterolemia; 
Type III Hyperlipoproteinemia, 
Homocystinuria, Familial HDL 
deficiencies (apolipoprotein A1), Familial 
Combined Hyperlipidemia 
Apopliporptein B-100;.
Lipoprotein lipase; Hepatic lipase;, 
Lysosomal acid lipase; 
Sphingomyelinase; Lecithin-
cholesterol acyltransferase; 
Apolipoproteins AII, AIV, CII, and 
CIII; proprotein convertase 
subtilisin/kexin type 9; ATP 
binding cassette protein subtype 
G5/8; Niemann-Pick type C1 
Homeostasis 
of blood 
pressure 
Insulin-resistant diabetes mellitus with 
acanthosis nigricans and hypertension 
Peroxisome proliferator-activated 
receptor-ǂ; Angiotensinogen; ; 
Angiotensin converting enzyme;  
Primary hypertension; 
Angiotensin II; Angiotensin II 
receptor, 11ß-ketoreductase; 
Cytochrome P450, family 1, 
subfamily B, polypeptide 1; 
Aldosterone synthase; Adducin; 
Nitric oxide synthase; Metafolin 
folate receptor; Thrombospondin 
Glucose 
metabolism 
Monogenic disorders leading to type 2 
diabetes mellitus (e.g. insulin receptor, 
glucokinase); Peroxisome proliferator-
activated receptor-ǂ, -Ǆ, -ǃ; 
Glucose transportersHuman 
leukocyte antigen locus DQ; 
Adiponectin; leptin receptor, 
melanocortin receptor 4; transcription 
factor 7-like 2; E-selectin 
Hemostasis Prothrombin; Factor V Leiden; Blood 
clotting disorders in conjunction with 
open foramen ovale; platelet-derived 
growth factor 
Clotting factors II, V, VII; 
Fibrinogen; Plasminogen activator 
inhibitor-1; Thrombomodulin; 
transforming growth factor-ǃ1 
Inflammatory 
response 
genes 
lInterleukin-6 and nuclear factor kappa-
light-chain-enhancer of activated B cell; 
connexin 37; 
Pyrin; Epithelial cell adhesion 
moleculeapolipoprotein A-I; 
Adenosine triphosphate-binding 
cassette transporter A1, and 
lecithin-cholesterol acyltransferase 
Oxidative 
mediators 
Homocystinuria; Paraoxone;, 
Methylenetetrahydrofolate reductase;
Cystathionine-beta-synthase; Nitric 
oxide synthase;
Adhesion 
mediators 
Collagen IIIa; Glycoprotein IIIa, E-selectin; 
vascular cell adhesion molecule-1; 
Epithelial cell adhesion molecule; 
Inter-cellular adhesion molecule 1 
Gene 
regulators/ 
Transcritpion 
factors 
Peroxisome proliferator-activated 
receptor-ǂ,Ǆ; Myocyte-specific enhancer 
factor 2A; Paraoxonase 1; GATA 
transcription factor-2 
Sterol regulatory element binding 
protein; Hepatocyte nuclear factor 
1-5; transcription factor 7-like 2 
Table 1. Summary of the important risk genes and disease pathways leading to the 
manifestation of coronary artery disease. 
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Familial hypercholesterolemia (FH) is a clinical expression for the presence of elevated 
concentrations of LDL, deposition of LDL-derived Chol in tendons, skin xanthomas, and 
premature CAD, and an autosomal dominant trait of either increased serum Chol or 
premature CAD. It is also characterized by increased levels of total Chol and LDL-C, which 
result in excess deposition of Chol in tissues, leading to accelerated atherosclerosis and 
increased risk of premature CAD. Autosomal dominant FH is caused by LDLR deficiency 
and defective Apo B, respectively. Deficient LDLR activity results in elevated circulating 
LDL-C leading to its accumulation within blood vessel walls, which may result in arterial 
plaque formation, and therefore eventually occlude the arterial lumen. As such, HDL-C is 
often reduced in homozygous FH, while Lp(a) levels are high when corrected for Apo A 
isoforms35. While this phenomenon is likely to underlie genetic factors, the greater majority 
of these genes remain to be identified.  
Autosomal recessive hypercholesterolemia (ARH) is a rare Mendelian dyslipidaemia 
characterized by markedly elevated plasma LDL levels, xanthomatosis, and premature 
CAD. LDLR function is normal, or only moderately impaired in fibroblasts from ARH 
patients, but their cultured lymphocytes show increased cell-surface LDL binding, and 
impaired LDL degradation, consistent with a defect in LDLR internalization36. Although the 
clinical phenotypes of ARH and homozygous FH are similar, autosomal recessive 
hypercholesterolaemia seems to be less severe, more variable within a single family, and 
more responsive to lipid-lowering drug therapy. In some individuals, the cardiovascular 
complications of premature atherosclerosis are delayed and involvement of the aortic root 
and valve is less common than in homozygous FH.  
Another form of FH, heterozygous familial hypercholesterolemia (HFH) is an autosomal 
dominant disorder known to be associated with elevated Chol levels and increased risk of 
premature CAD. The estimated prevalence of HFH is 0.2% in most populations of the world. 
Apparently, the prevalence of peripheral arterial disease is increased dramatically in FH 
subjects compared with non-FH controls. In addition, the intima-media thickness of the 
carotid and/or femoral artery is increased in FH subjects.  
Familial combined hyperlipidaemia (FCH) is a common heterozygous complex metabolic 
disorder characterized by (a) increase in cholesterolaemia and/or triglyceridaemia in at least 
two members of the same family, (b) intra-individual and intrafamilial variability of the 
lipid phenotype, and (c) increased risk of premature CAD. It is thought that in FCH elevated 
circulating levels of chylomicrons are broken down to produce atherogenic remnants 
through lipolysis of adipose cells, thereby contributing to the formation of atherosclerotic 
plaques. Thus, FCH is a common complex dominant disease condition associated with 
mixed hyperlipidaemia that accounts for up to 20% of premature CAD. The disease is 
sensitive to environmental effects. One of the roles of lipoprotein lipase is in the LDLR-like 
protein-mediated uptake of lipoprotein remnants in the liver and up to 20% of FCH patients 
show a genetic abnormality of this enzyme. FCH is very frequent (estimated prevalence: 
0.5%-2.0%) and is one of the most common genetic hyperlipidaemias in the general 
population, being the most frequent in patients affected by CAD (10%) and among acute MI 
(AMI) survivors aged less than 60 (11.3%). The disease is subject to wide-scale 
environmental confounding traits such as obesity and the metabolic syndrome which 
remain to be elucidated.  
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Hypertriglyceridaemia represents one of the attributes of metabolic syndrome and is present 
in the most common genetic dyslipidaemia, the FCH. The disease also appears to underlie 
the phenomenon of small dense LDL in most instances. These particles are found in families 
with various disorders including premature CAD and hyperapobetalipoproteinemia, FCP, 
LDL subclass pattern B, familial dyslipidaemic hypertension, and syndrome X, as 
components of the metabolic syndrome37. Their presence is often accompanied by increased 
TGs and low HDL. While overproduction of VLDLs by the liver and increased secretion of 
large, Apo B-containing VLDL is the primary metabolic characteristic of most of these 
patients, this atherogenic syndrome seems to encompass also subclinical inflammation and 
elevated procoagulants. Their production occurs as a result of TG hydrolysis by LPL in 
VLDL, leading to the generation of IDL and in turn LDL. In LDL, the Chol esters are then 
exchanged for TG in VLDL by the Chol ester transfer proteins (CETPs), followed by 
hydrolysis of TG by HL to produce the particles. Apparently, CETP mediates a similar lipid 
exchange between VLDL and HDL, producing a Chol ester-poor HDL. In adipocytes, a 
primary defect in the incorporation of free fatty acids into TGs may trigger reduced fatty 
acid trapping and retention by adipose tissue, leading to increased levels of free fatty acids 
in plasma, increased flux of free fatty acids back to the liver, enhanced production of TGs, 
decreased proteolysis of Apo B, and increased VLDL production. Alternatively, insulin 
resistance may promote reduced retention of free fatty acids by adipocytes also leading to 
the same process. These metabolic disorders are often accompanied by decreased removal of 
postprandial TGs. Genes regulating the expression of the major players in this metabolic 
cascade, such as LPL, CETP, and HL, may also modulate the expression of the small, dense 
LDL37. Irrespective of the source, small, dense LDL particles have a prolonged retention 
time in plasma, are more susceptible to oxidation because of decreased interaction with the 
LDLR, and enter the arterial wall more easily, where they are retained more readily.  
2.1.2 Glucose metabolism and coronary artery disease manifestation 
Glucose is the primary source of energy required for normal organ function. Its metabolism 
involves the processing of simple sugars in foods to be utilized to produce energy in the 
form of adenosine triphosphate (ATP). Once consumed, glucose is absorbed by the 
intestines and into the blood. Extra glucose is stored in the muscle and liver as glycogen, 
which is hydrolyzed to glucose through gluconeogenesis and released into the bloodstream 
when needed. While tissues such as the brain and red blood cells can only utilize glucose, 
others can also use fats. Glucose can also be produced from non-carbohydrate precursors, 
such as pyruvate, amino acids and glycerol. Insulin and glucagon work synergistically to 
keep blood glucose concentrations normal. Insulin is produced in the pancreas, where its 
secretion is increased by elevated glucose concentrations, gastrointestinal hormones and 
beta(ǃ)-adrenergic stimulation and can be inhibited by catecholamines and somatostatin. 
Accordingly, an elevated blood glucose concentration results in the secretion of insulin and 
glucose is transported into body cells, while glucagon has an opposite effect. Insulin exerts 
several functions that may influence the regulation of coronary vessel activity. Poor glucose 
metabolism as observed in insulin resistance is a primary cause for T2DM. Insulin resistance 
presents the impaired ability of either endogenous or exogenous insulin to lower blood 
glucose. It is typically characterized by decreased sensitivity and/or responsiveness to 
metabolic actions of insulin constituting a central feature of T2DM, obesity and 
dyslipidaemia, as well as a prominent component of hypertension and atherosclerosis that 
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are all characterized by endothelial dysfunction. In some insulin-resistant individuals, 
insulin secretion will begin to deteriorate under chronic stress (glucose toxicity) and overt 
diabetes will result. If not, individuals will remain hyperinsulinemic, with perhaps some 
degree of glucose intolerance, together with other hallmarks of the insulin resistance 
syndrome (IRS). Increased free fatty acids and lipid accumulation in certain organs are 
mediators of insulin resistance38.  
The insulin resistance syndrome (syndrome X, metabolic syndrome) is a multifactorial 
disorder with obesity, dyslipidaemia, atherosclerosis, hypertension, and T2DM acting 
together to shorten life spans23. While a growing number of single genetic diseases affecting 
energy metabolism have been found to produce the clinical phenotype, strong familial 
occurrences, especially in racially prone groups together with modern genetic approaches 
are beginning to unravel the polygenetic nature of the syndrome. However, the strong 
lifestyle factors of excessive carbohydrate and fat consumption and lack of exercise are 
important keys to its phenotypic expression. The natural history includes small foetal 
gestational age birth weight, excessive weight gains during childhood, premature puberty, 
an allergic diathesis, acanthosis nigricans, striate compounded by gynecomastia, 
hypertriglyceridaemia, hepatic steatosis, premature atherosclerosis, hypertension, polycystic 
ovarian syndrome, and focal glomerulonephritis appearing increasingly through adolescence 
into adulthood. T2DM, which develops because of an inherent and/or an acquired failure of 
an insulin compensatory response, is increasingly seen from early puberty onward, as is 
atheromatous disease leading to CAD and stroke23. A number of physiological alterations of 
glucose metabolism including hepatic overproduction of glucose, and reduced glucose 
utilization by peripheral tissues as a result of insulin resistance contribute to the development 
of the metabolic manifestations of this disease. Ultimately, pancreatic failure and reduced 
insulin secretion lead to hyperglycemia and the diabetic state.  
Inherited metabolic disorders contribute importantly to adverse cardiovascular outcomes 
and affect all tissue types39. Primary defects in energy balance that produce obesity (and 
visceral adiposity in particular) are sufficient to drive all aspects of the metabolic syndrome. 
Common obesity is polygenic, involving complex gene-gene and gene-environment 
interactions, which explain the multi-factorial obese phenotypes. Obesity also leads to a 
proinflammatory and prothrombotic state that potentiates atherosclerosis. Fat-derived 
adipokines, including tumor necrosis factor-alpha (TNF-ǂ) and adiponectin have also been 
recently implicated as pathogenic contributors or protective factors. Distinct MAPK-
dependent insulin-signaling pathways (largely unrelated to metabolic actions of insulin) 
regulate secretion of the vasoconstrictor endothelin-1 from endothelium. Endothelial 
dysfunction is often characterized by pathway-specific impairment in phosphatidylinositol 
3-kinase (PI3K)-dependent signaling that contributes to a reciprocal relationship between 
insulin resistance and endothelial dysfunction. Thus, for example, PI3K-dependent insulin-
signaling pathways regulating endothelial production of nitric oxide share parallels with 
metabolic insulin-signaling pathways. These and other cardiovascular actions of insulin 
contribute to coupling metabolic and hemodynamic homeostasis under healthy conditions.  
2.1.3 Blood pressure homeostasis and coronary heart disease manifestation 
Blood pressure is the pressure exerted by circulating blood on vessel walls and presents one 
of the principal vital signs of life. In general, blood pressure refers to arterial pressure of the 
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systemic circulation. It can be influenced by various factors including the heart pumping 
rate, blood volume, vascular resistance and blood viscosity40. Although the endogenous 
regulation of arterial blood pressure is not yet completely understood, a number of 
mechanisms have been defined. These include the baroreceptor reflex, the renin-angiotensin 
(RAS) system and aldosterone release. Hence, the renin-angiotensin-aldosterone system 
(RAAS) constitutes a hormonal system primarily responsible for regulating blood pressure 
and fluid balance. Low blood volume induces secretion of renin in the juxtaglomerular cells 
in the kidneys. Renin in turn stimulates the production of angiotensin I from 
angiotensinogen, which is converted to angiotensin II (Ang II) by the ACE. Ang II induces 
vasoconstriction of the vessels resulting in increased blood pressure. It also stimulates the 
secretion of aldosterone from the adrenal cortex, which mediates an increase in the 
reabsorption of sodium and water from the kidney tubules into the blood. This in turn 
increases the fluid volume in the body and therefore the blood pressure. Increased RAAS 
activity leads to high blood pressure, and therefore to hypertension.  
Hypertension is a vascular disease that may influence the viability of blood vessels. The 
disease is inheritable (primary) or may underlie environmental causes such as high salt 
consumption level. Evidence also suggests that Ang II plays an important role in the 
regulation of structure and function of both the heart and vessel wall. Under pathologic 
conditions, the ability of the heart and vessel wall to generate Ang II is increased, because of 
increased ACE expression. Hypertension is thought to correlate with impaired glucose 
tolerance. However, although the mechanism is not yet fully understood, this has been 
partly attributed to rapid nutrition and lifestyle transitions contributing to acceleration of 
obesity-related non-communicable diseases in some ethnic populations41. These include 
body phenotypes, such as high body fat, high truncal, subcutaneous and intra-abdominal 
fat, and low muscle mass, biochemical parameters such as hyperinsulinemia, 
hyperglycemia, dyslipidaemia, hyperleptinemia, low levels of adiponectin and high levels 
of C-reactive protein as well as procoagulant state and endothelial dysfunction41. Major 
atherogenic risk factors are likely mediators in the oxidative modification of DNA, and an 
increase in oxidative stress may derive from oxidatively damaged mitochondria42.  
2.1.4 Regulation of inflammatory processes and coronary artery disease 
Inflammation is part of the complex biological response of vascular tissue to harmful 
stimuli, such as pathogens, damaged cells and irritants44. It is a protective mechanism the 
organism employs to remove injurious stimuli and to initiate the healing process. 
Inflammation can be classified as acute or chronic, whereby it presents the initial response of 
the body to harmful stimuli. This is achieved by the increased movement of plasma and 
leukocytes (especially granulocytes) from the blood into the injured tissues. A cascade of 
biochemical events propagates and matures the inflammatory response, involving the local 
vascular system, the immune system and various cells within the injured tissues. Prolonged 
inflammation, known as chronic inflammation, leads to a progressive shift in the type of 
cells present at the site of inflammation and is characterized by simultaneous destruction 
and healing of the tissue from the inflammatory process. Vascular endothelial dysfunction 
underlies the genesis and progression of numerous diseases. Among others, it has recently 
emerged as an early step in the development of atherosclerosis and is mainly characterized 
by a reduction in the bioavailability of nitric oxide. All of the traditional cardiovascular risk 
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factors, including dyslipidaemia, arterial hypertension, hyperglycemia and diabetes, are 
associated with endothelial dysfunction, and oxidized LDLs, the renin-angiotensin axis and 
insulin resistance play important roles in the pathogenesis of impaired endothelial function. 
The increased expression of adhesion molecules and pro-inflammatory cytokines leads to 
abnormal endothelium-dependent vasodilatation. Apart from perturbation in systems 
regulating vasoconstriction and vasodilatation, ailments such as diabetes mellitus contribute 
equally to the formation of the plaque in blood vessels. Also, the immune system has 
recently been implicated in the pathogenesis of endothelial dysfunction and atherosclerosis 
with a particular regard towards autoimmunity due to the high prevalence of the 
atherosclerotic process in systemic autoimmune diseases. Dysfunction of HDL and its APOs 
A-I, A-II, and C-III has been observed in general populations, whereby high concentrations 
of HDL or Apo A-I in individuals with diabetes or CAD were found to reveal dysfunction in 
some population-based studies. It has been suggested that dysfunctional HDL particles even 
become proinflammatory or lose atheroprotective properties. While HDL dysfunctionality 
has been closely linked to obesity and low-grade inflammation, it appears nonetheless to act 
partly independently of them45.  
Chemokines are important mediators of angiogenesis, hematopoiesis and leucocyte 
trafficking. Chemokine Ligand-18 (CCL18)/pulmonary and activation-regulated chemokine 
(PARC) is a circulating chemokine that plays a role in injury healing, physiological homing 
of mononuclear blood cells and inflammatory responses. CCL18/PARC is also expressed in 
atherosclerotic plaques, and its levels have been associated with decreased cardiac function, 
decreased exercise capacity and increased inflammatory parameters including interleukin-6 
(IL-6) and high sensitive C-reactive protein46. More importantly high CCL18/PARC levels 
appear to present an independent predictor of future cardiovascular events46  
2.1.5 Environment and coronary artery disease management 
Like all other risk factors of CAD, the type of food one consumes and style of life an 
individual leads, are equally important components for pathways leading to the disease, 
as they affect directly some of the risk factors, such as increased circulating Chol and 
predisposition to obesity. This is a chronic disease with a multifactorial etiology including 
genetics, environment, metabolism, lifestyle, and behavioral components which have been 
shown to contribute to the development of obesity45. Elevated body mass index, 
particularly caused by abdominal or upper-body obesity, has been associated with a 
number of diseases and metabolic abnormalities, many of which have high morbidity and 
mortality. These include hyperinsulinemia, insulin resistance, T2DM, hypertension, 
dyslipidaemia, CAD, and certain other malignancies. Besides, it appears that sedentary 
subjects with upper-body and visceral obesity who have the metabolic syndrome tend to 
be at higher risk for hypertriglyceridaemia in response to high-sucrose and high-
carbohydrate diets47. Thereby, moderate weight loss mitigates the effect. 
Hyperinsulinemia or insulin resistance may play a role in promoting higher rates of 
VLDL synthesis and hypertriglyceridaemia in obesity, but the mechanisms remain 
unclear47. Some of these effects may be gender-related. For example, high dietary 
glycemic load is associated with higher serum triacylglycerol concentrations and greater 
risk of CAD in women47, and cigarette smoking in overweight women with low-grade 
inflammation appears to offer limited protection against cardiometabolic risk45.  
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Postprandial lipemia is traditionally defined by the extent and duration of the increase in 
plasma TGs in response to a fat-enriched meal. Alimentary lipemia has been associated with 
CAD, in a fashion that is influenced by both genetic and environmental factors. Disease 
processes, such as dyslipidaemia, hypertension, glucose and insulin metabolism, lifestyle 
habits, such as eating and exercise patterns, as well as socioeconomic status aggregate in 
families with CAD. The degree of risk associated with a family history varies with the 
degree of relationship and the age at onset of disease. Postprandial lipoprotein metabolism 
is modulated by background dietary pattern as well as meal composition including fat 
amount and type, carbohydrate, protein, fibre, alcohol, and several lifestyle conditions such 
as physical activity, tobacco use, physiological factors including age, gender, menopausal 
status and pathological conditions such as obesity, insulin resistance, diabetes mellitus. 
Overall, the variability in postprandial response is important and complex, and the 
interactions between nutrients, dietary or meal compositions and gene variants need further 
investigation. Furthermore, extremely low fat dietary habits or major gene interactions may 
influence the lipid profile and the excess cardiovascular mortality observed in heterozygous 
FH, whereas minor gene determinants do not seem to play any significant role. All other 
factors put into consideration, the prevalence of the disease may vary among populations, 
due to differences in the awareness of the disease in a given population.  
2.2 Early onset coronary artery disease 
Acute coronary syndrome (ACS) is a manifestation of myocardial infarction (MI) at young 
age, usually described as being under 45 years of age. It is usually associated with coronary 
thrombosis, and chest pain can also be precipitated by anemia, bradycardias or tachycardias. 
AMI represents the main thrombotic complication of CAD, with a presence of 
approximately 9% of the new events of MI occurring in patients. The condition is produced 
by development of a thrombus at the site of an atherosclerotic plaque that initiates abrupt 
arterial occlusion, with ischemia and cell death. Evidence of significant disease at coronary 
angiography suggests the presence of a premature atherosclerotic process. Based on the 
appearance of the electrocardiogram (ECG), they are also defined as non-ST elevation 
myocardial infarction (NSTEMI) and ST segment elevation myocardial infarction (STEMI) or 
unstable angina48, whereby STEMI constitutes about 30%, NSTEMI 25% and unstable angina 
38% of the affected individuals. Unstable angina occurs suddenly often at rest with minimal 
exertion, or at lesser degrees of exertion than a previous angina. MI at a young age is 
commonly characterized by evidence of multiple cardiovascular risk factors and by a 
favorable prognosis in short- and medium-term follow-up. Thus, AMI reflects a degree of 
damage to the coronaries by atherosclerosis. Apparently, the type of ischemic event shows 
gender-specific differences. Thus, in women it appears to present more frequently with 
unstable angina and NSTEMI, whereas men will have ACS with STEMI48-50. However, it is 
still questionable whether this gender association has any genetic background to it.  
Several modifiable factors such as hypertension, diabetes, smoking, obesity, and 
hypercholesterolemia are involved in AMI manifestation. However, in a large number of 
patients with AMI, modifiable risk factors are not present. Furthermore, apart from early 
onset of CAD, recurrent coronary events in the young also present an important problem. 
Recently, the role of Lp(a), homocysteine, inflammation and infection as prime culprits in 
the pathogenesis of CAD has become a subject of intense research and debate. Specifically, 
hyperhomocysteinemia is a risk factor of recurrent coronary event in the young and an 
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element of gene-environment interaction may also contribute significantly to its 
manifestation. Monogenic disorders are seen in approximately 5% of premature CAD cases, 
and this prevalence is higher in populations with the founder effect. Family history of MI is 
positively associated with the risk of early MI in women. While the association with parental 
history of MI is mediated through the clustering of other common risk factors, the 
association of sibling history of MI with early-onset MI in young women is only partially 
explained by the clustering of established and newly-identified risk factors51.  
Heredity has a significantly great share in AMI. Particularly, familial lipidaemic disorders 
play a pivotal role in early onset of CAD. Familial lipoprotein disorders are seen frequently 
in subjects with premature CAD. In FH, early CAD is a complex trait that results from a 
large monogenic component of susceptibility due to elevated LDL-C even in the absence of 
any other risk factors. Increased LDL and decreased HDL-C predict premature CAD, as do 
elevated levels of Apo B or reduced levels of Apo A. The metabolic abnormality in many 
FH-affected individuals is overproduction of Apo B-containing lipoproteins causing 
elevated levels of plasma Chol, TGs, or both. Low levels of HDL-C and an abundance of 
dense LDL particles are other features contributing to the high association of this disorder 
with premature CAD. Although for most children the process of atherosclerosis is 
subclinical, dramatically accelerated atherosclerosis occurs in some pediatric disease states, 
with clinical coronary events occurring in childhood and very early adult life. A striking 
example is found in children who have the homozygous form of FH with extremely high 
levels of LDL-C, whereby severe atherosclerosis and CAD often develop during the first 
decades of life.  
Among patients with CAD onset before the age of 55, about 5% of cases are attributable to 
HFH, a monogenic disorder that affects about 1 in 500 people, with a higher prevalence in 
certain subpopulations. The disease manifests with severe hypercholesterolemia since birth 
(Chol levels >5-6 the upper normal limit), which, if untreated, leads to early onset 
accelerated atherosclerosis and premature coronary death, usually before the second or 
third decades of life. It occurs primarily as an autosomal dominant disorder with a gene-
dosage effect. The clinical phenotype of HFH is characterized by increased plasma levels of 
total Chol and LDL-C, tendinous xanthomata, and premature symptoms of CAD. The 
disease is characterized by Chol deposits affecting the corneas, eyelids and extensive 
tendons, elevated plasma concentrations of LDL-C and accelerated vascular disease, 
especially CAD. It is inherited as an autosomal dominant disorder with homozygotes 
having a more severe phenotype than do heterozygotes. Dyslipidaemic states associated 
with premature atherosclerotic disease and high cardiovascular risk are characterized by a 
disequilibrium related to an excess of circulating concentrations of atherogenic lipoproteins 
relative to those of atheroprotective HDL, thereby favouring arterial Chol deposition and 
enhanced atherogenesis. In such states, CETP activity is elevated and contributes 
significantly to the Chol burden in atherogenic Apo B-containing lipoproteins6,7.  
3. The genetic basis of coronary artery disease 
Variation in human genes is a result of structural alteration(s) in the sequence of the gene 
due to a modification in any one of the DNA bases, producing different forms of the gene 
known as polymorphisms. These polymorphic changes may or may not lead to changes in 
amino acids, consequently constituting an alteration in the functional expression of the 
www.intechopen.com
 
Gene Polymorphism and Coronary Heart Disease 
 
21 
resultant protein. The types of gene variants are defined as missence, silent, nonsense or 
Frameshift mutations, depending on the resultant effect of the changes on the protein 
product. These sequence variations are classified as large-scale or small-scale mutations, and 
may influence any type of protein, including structural, signaling, or enzymes engaged in 
various functions. Large-scale mutations usually lead to a gain or loss of chromosomal 
regions or translocation of parts of a chromosome, whereas small-scale mutations are 
nucleotide-based substitutions, deletions or insertions leading to new gene products, as well 
as gene, protein and phenotypic expression. One of the most important findings in recent 
times is the recognition of the fact that sequence variations in the human genes are confined 
to single nucleotide polymorphism (SNPs). The number of SNPs varies within one gene 
from one population to another. It is also thought that more than 50% of all coding SNPs 
produce a predictable change in the protein sequence. This fact points to a high level of 
human protein diversity, with potentially great impact on disease manifestation and modes 
by which patients respond to drug therapy.  
Sequence variations implicated in complex diseases such as CAD are often found in genes 
regulating diverse mechanisms (e.g. lipid metabolism, glucose handling, blood pressure 
regulation, or vascular contractility). Indeed, virtually all risk factors for the disease 
themselves underlie genetic background. Besides, many of these risk factors seem to share 
some genomic regions and/or gene variants among themselves as well as with CAD, 
pointing to common loci and possible gene-gene interactions as a mechanism for such 
complex diseases. An added intricacy to the situation with complex diseases, such as CAD, 
is the fact that changes in various genes may be related to clusters of dysfunctions that also 
contribute to the disease, rendering it oft difficult to decipher exactly which factors may be 
the primary or secondary culprits. Hence, ultimately manifestation of CAD is a product of 
interaction of environmental factors with alteration in genes that regulate numerous 
pathways. This section summarizes some of the important genes engaged in the different 
pathways leading to its manifestation. The catalogue of gene discussed is far from being 
exhaustive, but simply intended to reflect on some of the established pathways, as well as 
findings that have recently stimulated further search into their relevance for CAD.  
3.1 Pathways regulating lipid metabolism 
Understandably, alterations in genes regulating circulation Chol levels and its metabolites 
should occupy a key position among the disease pathways leading to CAD manifestation. 
As such, lipidaemic disorders leading to an increase in circulating Chol could theoretically 
result from mutations in genes involved in any of the various pathways regulating its 
homeostasis. Hence, perhaps by far the most well-studied risk pathways for CAD are those 
leading to FH, an autosomal defect related to mutations in the LDLR, the Apo B and the 
PCSK9 genes. However, mutations in several other genes, such as LDLR adapter protein 1 
(LDLRAP1) Apo A-I, Apo A-IV, Apo A-V, Apo C-III, can also lead to a phenotype similar to 
the disease. In humans, LDLR mutations induce hypercholesterolemia and, subsequently, 
Chol deposition to a variable degree, not only confirming the pathogenetic role of LDLR but 
also highlighting the existence of additional factors in determining the phenotype. 
Apparently, receptor-negative mutations result in a more severe phenotype than do 
receptor-defective mutations52. At least five specific monogenic disorders, are known to be 
related to this phenomenon. These are familial hypercholesterolemia, familial ligand-
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defective Apo B, autosomal recessive hypercholesterolemia, sitosterolemia and cholesterol 
7-alpha-hydroxylase deficiency. The diseases may occur in the form of a Mendelian (caused 
by a defect in a single gene) or as a complex trait (resulting from an interaction of genetic 
predisposition and environmental factors). Several loci including LDLR-associated protein, 
PCSK9 and ATP-binding cassette transporters ABCG5 and ABCG8 have been identified for 
monogenic hypercholesterolemia. Functionally, ABCG5 and 8 pump sterols out of the 
hepatic and intestinal cells into bile and intestinal lumen, respectively. A number of PCSK9 
variants have been identified, some of which are gain-of-function mutations causing 
hypercholesterolemia by a reduction of LDLR levels, while loss-of-function variants have 
been associated with a reduction of LDL-C levels and a decreased risk of CAD53. 
Furthermore, at least nine of the apolipoproteins known to play a major role in lipid 
metabolism have been implicated in influencing plasma levels of HDL, VLDL, LDL 
chylomicrons or TGs54. Mutations in the Apo B gene can result in a phenotype that is 
clinically indistinguishable from FH, and have also been shown to be associated with CAD. 
Although many studies indicate that the FH phenotype is influenced by other genetic and 
environmental factors, it remains unclear whether or not these are synergistic interactions or 
simply additive effects52. Furthermore, although HFH is genetically heterogeneous, it is 
most often caused by heterozygous mutations in the gene encoding the LDLR.  
Another form of FH, the ARH has been associated with the insertion mutation in a 
phosphotyrosine binding domain of the so-called ARH protein55, encoding a cellular 
adaptor protein required for LDL transport, and consequently for internalization of LDLs in 
the liver. This protein is thought to function as an adaptor protein that couples LDLR to the 
endocytotic machinery36. The phenotypic expression of this homozygous FH appears to be 
dominated by the consequences of the LDLR gene mutations. An autosomal recessive form 
of FH caused by loss-of-function mutations in LDLRAP1a has also been reported. In 
heterozygous FH, however, the underlying mutational LDLR type determines only to a 
much lesser extent, if any, the variable phenotypic expression. Conversely, some PCSK9 
loss-of-function mutations resulting in low levels of LDL-C appear to protect against CAD56 57. 
However, despite compelling evidence indicating that PCSK9 impairs the LDLR pathway, its 
role in Chol metabolism remains incompletely defined. Additional atherogenic risk factors of 
environmental, metabolic, and genetic origin are presumed to influence the clinical phenotype 
in FH. Other risk factors include the LPL gene which is thought to present a risk factor for 
dyslipidaemia, characterized by hypertriglyceridaemia and low HDL-C levels which increases 
with age and weight gain, and is associated with CAD and T2DM.  
The HDL-C levels are under considerable genetic control with heritability estimates of up to 
80%, and low HDL-C syndromes have generally been correlated with an increased risk of 
CAD. The cardioprotective effects of HDL-C have been attributed to its role in reverse Chol 
transport, its effects on endothelial cells, and its antioxidant activity58. On the other hand, 
relative HDL-C deficiency states have been associated with the ATP binding cassette protein 
(ABCA1), Apo A1 and lecithin cholesteryl acyl transferase defects. However, although 
numerous candidate genes contribute to the low HDL-C phenotype, their impact on CAD is 
heterogeneous, single gene abnormalities responsible for HDL-C deficiency states may have 
variable effects on atherothrombotic risk, reflective of diverse gene-gene interactions and 
gene-environmental relationships. Other potentially important candidates involved in low 
HDL-C syndromes in humans include Apo C3, LPL, sphingomyelin phosphodiesterase 1, 
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and glucocerebrosidase. Molecular variation in ABCAI and Apo AI and partly lecithin 
cholesteryl acyl transferase deficiency have been associated with increased CAD, while 
some of the Apo A1 variants, such as Apo A1 Milano and Apo A1 Paris have been associated 
with reduced risk. Endothelial lipase gene polymorphisms have also been associated with 
HDL-C concentrations59. This lipase participates in HDL metabolism by promoting the 
turnover of HDL components and increasing the catabolism of Apo A-I59, which 
distinguishes itself from other TG lipases in showing the highest activity on HDL59. 
Similarly, mutations in the CETP gene associated with CETP deficiency are characterized by 
high HDL-C levels and reduced cardiovascular risk.  
In contrast to FH, which is caused by mutations in a number of affected genes, the genetics 
of FCH have remained obscure and very few definite candidate genes have been identified 
thus far. Of these, the strongest evidence links the lipid components of FCH to intronic 
variants in the upstream transcription factor 1 (USF1) gene on chromosome 1q21-23. 
Modifying genes, particularly those that influence the high TG trait, include apo C3 and 
apolipoprotein A5 (apo A5). Apo A5 is a member of the apolipoprotein Apo A1/C3/A4 gene 
cluster, and is important in regulating plasma TG levels. It also represents a downstream 
target of USF1, implicating a USF1-dependent pathway in the molecular pathogenesis of 
dyslipidemias60. However, the relationship of USF1 polymorphisms with diabetes and the 
metabolic syndrome, which co-localize to this region and are also associated with mixed 
hyperlipidaemia, has yet to be defined. Additionally, Apo AV is an activator of LPL, linked 
to familial hypertriglyceridaemia and FCH to upstream stimulatory factor 161. A case study 
of a patient with ǂǃ-lipoproteinaemia suggested that the hypertriglyceridaemia seen in 
patients with FCH may result from an abnormality in microsomal TG transport protein 
function. A direct relationship between the post-prandial TG levels and LDL-C levels in the 
fasting state of patients with FCH and sporadic hypercholesterolaemia has also been 
postulated, which increases considerably when all the MI survivors are considered 
independent of age. The USF1 has been linked with familial combined hyperlipidaemia in 
some ethnic groups. Currently, genetic and functional evidence is supportive of a role for 
the USF1 in the etiology of FCP and its component traits, although the mechanism still 
remains largely unknown62. While the genetic defect remains unknown, linkage to the 
region of the Apo AI- CIII- AIV gene cluster on chromosome 11 has been implicated. 
Other mutations, especially the truncation-causing mutations in Apo B and MTP can cause 
familial hypobetalipoproteinemia, characterized by hypercholesterolemia and resistance to 
atherosclerosis63. Therefore, in genetic dyslipidaemia elevated Apo B levels and reduced 
Apo A levels (or increased Apo B/AI ratio) differ and predict premature CAD64. One of the 
most extensively studied lipoprotein genes in this respect is the apo E, which has been linked 
with various forms of lipidaemic disorders. An example of an apo E-mediated, autosomal 
recessive, lipid disorder is familial dysbetalipoproteinemia (FD). The gene exists in three 
allelic forms (epsilon2 (ε2), ε3 and ε4 coding for isoforms E2, E3, and E4 and having different 
binding affinities for the apo E receptors. This genetic variation is associated with different 
plasma lipoprotein levels, different response to diet and lipid-lowering therapy, and a 
variable risk for cardiovascular disease and Alzheimer's disease. While the ε2 allele is 
associated with elevated TG levels, the ε4 allele is associated with increased Chol levels. The 
ε2/ε2 genotype is thought to present the most common cause for hyperlipoproteinemia type 
III. However, although several studies support the role of apo E polymorphism in CAD 
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either directly or indirectly via its influence on lipid and lipoprotein levels, there are some 
studies which show lack of such relationships. 
3.2 Pathways regulating blood pressure 
Given that hypertension, diabetes, dyslipidaemia, and obesity exhibit a substantial heritable 
component, it is to be expected that important genes encoding proteins related to these 
pathways may predispose individuals to this cluster of cardiovascular risk factors. 
Specifically, as the core regulator of systemic blood pressure, and being involved in the 
cardiovascular homeostasis, several polymorphisms in genes of the RAAS system have been 
found to have pleiotropic effects on cardiovascular disorders. A constituent of this system is 
angiotensinogen (AGT), a serum renin substrate glycoprotein synthesized in the liver, which 
is released as the precursor of angiotensin, the hormone that forms part of the systemic 
blood pressure regulatory system. Risk variants in this gene have been identified that lead 
not only to hypertension65,66, but also to CAD67-70. Apart from the AGT, several other genes 
engaged in regulating components of the RAAS pathway have also been identified as 
constituting risk for primary hypertension. These include among others, the alpha(ǂ-) 
adducin (ADD1)71, ACE72-75, nitric oxide synthase76, metafolin folate (methyl 
tetrahydrofolate; MTHF) receptor (MTFHR)77 and thrombospondin (THBS) genes78,79. The 
THBSs are a 5-member gene family that mediates cell-cell and cell-matrix interactions. These 
proteins are either trimers or pentamers, and their functions depend on their abilities to 
interact with numerous extracellular ligands and cell surface receptors through the multiple 
domains that compose each subunit. Thus, polymorphisms in 3 THBS genes encoding 
THBS1, THBS2, and THBS4 were proposed to modulate the risk of premature CAD78,79 and 
MI80-82. Interestingly, literally all of these genes have also been implicated in CAD 
manifestation. However, the important question remains as to whether their role in CAD is 
by virtue of their influence on the blood pressure control or some other signaling links may 
exist among the pathways involved in the disease process.  
3.3 Pathways regulation glucose metabolism 
The impact of T2DM as a primary cause for CAD has now become common knowledge. In 
fact, diabetic patients are thought to have a 3-fold higher risk of developing 
atherosclerosis and its clinical complications as compared to non-diabetic individuals. 
Part of the cardiovascular risk associated with this disease is probably due to genetic 
determinants influencing both glucose homeostasis and the development of 
atherosclerosis. Besides, T2DM frequently coexists with other cardiovascular risk factors 
like arterial hypertension, central obesity and dyslipidaemia in the manifestation of CAD. 
Several genes including ADIPOQ and peroxisome proliferator-activated receptor (PPAR) 
genes have been implicated in manifestation of metabolic syndrome (MS)83,84. 
Adiponectin (ADIPOQ) is an adipocyte-derived hormone and an essential modulator of 
insulin sensitivity. It is abundantly secreted by adipocytes, plays important roles in lipid 
and glucose metabolisms, and has direct anti-inflammatory and anti-atherogenic effects. 
Since it modulates several metabolic processes, it is thought to play an important role in 
the suppression of the metabolic derangements that may lead to MS. It may serve as an 
important biomarker for metabolic syndrome, and some of its common polymorphisms 
have been associated with the phenotypes related to body weight, glucose metabolism, 
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insulin sensitivity, and risk of T2DM and CAD85. While circulating ADIPOQ is involved 
in the atherosclerotic process and has been associated with cardiovascular disease as well 
as obesity, insulin resistance, metabolic syndrome, and T2DM83,84,86,87, its relationship with 
the early onset of atherosclerosis in hyperlipidaemia is still not completely understood.  
The PPAR-ǂ, -Ǆ, -ǃ are members of the nuclear receptor superfamily of ligand-activated 
transcription factors that have central roles in the storage and catabolism of fatty acids. All 
three PPARs are activated by naturally occurring fatty acids and fatty acid metabolites, 
indicating that they function as the fatty acid sensors of the body. Hence, they constitute 
major regulators of energy homeostasis. They not only control lipid metabolism, but also 
regulate vascular diseases, such as atherosclerosis and hypertension, as well as the 
expression of genes involved in fatty acid ǃ-oxidation. Specifically, PPAR-Ǆ plays a critical 
role in adipocyte differentiation and serves as the receptor for the glitazone class of 
insulin-sensitizing drugs used in the treatment of T2DM. PPARǃ polymorphisms are 
associated with plasma lipid levels, body mass index and the risk for diabetes and CAD88. 
PPARǄ2 variants have also been shown to influence insulin sensitivity in interaction with 
ADIPOQ or to influence plasma ADIPOQ levels. It has recently been suggested that 
PPARs may present a functional link between obesity, hypertension and diabetes. 
However, in contrast to PPARǂ and PPARǄ, relatively little is known about the biology of 
PPARǃ, although recent findings suggest that this subtype has a role in lipid homeostasis 
also.  
Candidate gene variants for polygenic obesity appear to disrupt pathways involved in the 
regulation of energy intake and expenditure and include adrenergic receptors, uncoupling 
proteins, PPARG, POMC, MC4R and a set of variants in the FTO locus. Notably, the FTO 
gene is the most robust gene for common obesity characterized to date, and recent data 
shows that the FTO locus seems to confer risk for obesity through increasing energy intake 
and reduced satiety. Gene variants involved in pathways regulating addiction and reward 
behaviours may also play a role in predispositioning to obesity89. Other obesity-related 
genes including ADIPOQ, leptin receptor, and fat mass obesity-related genes have also been 
described with respect to manifestation of metabolic syndrome and CAD/MI90. While 
genes, such as the PPARs91 have been discussed as independent risk for CAD88, several of 
them may share common variants for metabolic syndrome with CAD/MI, among 
themselves and/or with others, including Ang II92, AMP deaminase-193 and ACE91 genes. 
For example, the risk of acquiring CAD in patients with T2DM appears to increase 
significantly in the presence of the several gene variants such as those of the transcription 
factor 7-like 2 (TCF7L2)94 and E-selectin genes95. Other genes associated with CAD include 
the C5L2, a stimulator of TG synthesis or glucose transport and constitutes a functional 
receptor of acylation-stimulating protein96. Together, these data only reveal the complexity 
of mechanism involved in disease pathways regulating CAD and its risk factors.  
A rare genetic form of insulin resistance is Dunnigan-type familial partial lipodystrophy 
(FPLD), which is characterized by loss of subcutaneous fat from extremities, trunk, and 
gluteal region. It is always accompanied by insulin resistance and hyperinsulinemia, often 
with hypertension, dyslipidaemia, T2DM and early endpoints of atherosclerosis. FPLD is 
thought to result from mutated LMNA, which encodes nuclear lamins A and C. Familial 
studies indicate that dyslipidaemia precedes the plasma glucose abnormalities in FPLD 
subjects with mutant LMNA, and that the hyperinsulinemia is present early in the course of 
www.intechopen.com
 
Coronary Artery Disease – New Insights and Novel Approaches 
 
26
the disease. Plasma leptin is also markedly reduced in subjects with FPLD due to mutant 
LMNA. Thus, a defect in the structure and function of the nuclear envelope can result in a 
phenotype that shares many aspects with the common syndrome of insulin resistance.  
3.4 Pathways regulation smooth muscle cellular viability and function 
Since inflammatory mechanisms play a central role in mediating all phases of 
atherosclerosis, genes encoding for inflammatory or anti-inflammatory molecules are 
candidates for the risk of developing atherosclerosis. Genetic variability affecting many 
functional areas such as lipid and energy metabolisms, hypertension and haemodynamic 
mechanisms, blood clotting homeostasis, inflammation, and matrix turnover in the vascular 
wall will have an impact on the development of macrovascular complications in diabetic 
patients. During atherogenesis intercellular communication via gap junctions as well as cell 
membrane channels linking the cytoplasmic compartments of adjacent cells play a critical 
role. The component protein subunits of these channels, called connexin (Cx), belong to a 
multigene family. Cx37 is involved in growth, regeneration after injury and ageing of the 
endothelial cells, pointing to a potential role in atherosclerosis. A variant of the Cx37 gene 
has been associated with thickening of the carotid intima and therefore CAD97. Recently a 
higher prevalence of pro-inflammatory polymorphisms of several genes including pyrin, 
epithelial cell adhesion molecule (EPCAM), Cx37 and PCR genes and a lower prevalence of 
anti-inflammatory polymorphisms, such as the TLR4, IL10 and CCR5Δ32) has been 
documented98,99, suggesting early MI could be associated with a genetic predisposition to an 
intense inflammatory response, linked also to an hyperviscosity syndrome98,99. Intima media 
thickness studies have provided evidence that hypoalphalipoproteinemia due to mutations 
in apo A-I, ABCA1, and LCAT is associated with increased progression of atherosclerosis100. 
In contrast, hyperalphalipoproteinemia as a result of loss of CETP function is associated 
with unaltered atherosclerosis progression.  
The generation of oxidative stress is believed to be an important cause of DNA damage in 
atherosclerosis. Under oxidative stress, both blood monocytes and plasma lipoproteins 
invade the arterial wall, leading to their exposure to atherogenic modifications101,102. Hence, 
increased oxidative stress has been implicated in the pathogenesis of the atherothrombotic 
process. A recent addition to the list of genes thought to be involved in oxidative stress are 
the paraoxonases (PONs), a family of closely related antioxidants encoded by at least three 
clustered genes (PON1, PON2 and PON3) on chromosome 7q. The human PON1 is an HDL-
associated arylesterase that hydrolyzes paraoxon103. It is thought to exert an antiatherogenic 
effect by protecting LDLs against oxidation104,105 partly by slowing down the accumulation 
of lipid peroxides in LDLs under oxidizing conditions. Understandably therefore, 
alterations in the PON1 gene are implicated in dyslipidaemic disorders. Furthermore, free 
radical production in the immediate postrecanalization phase after thrombotic occlusion of a 
major coronary artery in humans is associated with MI106. The NADPH oxidase system as a 
main source of reactive oxygen species in vascular cells has been implicated in development 
and progression of CAD. In contrast, some gene variants, such as c.-930A>G in the promoter 
region of p22-PHOX gene have been shown to have protective effects107.  
Apart from inflammatory processes, alterations in genes regulating blood cell formation 
(hematopoiesis) and blood coagulation mechanisms constitute important cell function-
related risk for CAD. The fraction of immature platelets is increased in ACS, especially in 
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the acute phase of STEMI108. Immature platelets with an increased hemostatic potential may 
contribute to coronary thrombus formation. Recently a quantitative trait locus 12q24 
associated with mean platelet volume and platelet count has been implicated as a risk locus 
for CAD109. Polymorphisms in genes regulating various aspects of hematopoiesis and blood 
coagulation processes including leptin110, the GATA transcription factor GATA-2 have also 
been implicated in CAD. GATA-2 is an important regulator of hematopoiesis. Among 
others, glycoprotein growth factors regulate the proliferation and maturation of the cells 
that enter the blood from the marrow, as well as causing cells in one or more committed cell 
lines to proliferate and mature. Other recently added culprits for CAD include the lipase A, 
lysosomal acid, cholesterol esterase (LIPA), platelet-derived growth factor (PDGF), 
ADAMTS7-MORF4L1, and KIAA1462111 genes.  
3.5 Gene and mRNA regulatory pathways 
One of the most exciting findings in recent times is the discovery of several loci in DNA 
regions that regulate transcription rather than the coding regions for protein as risk 
sequences for disease. As such, several transcription factors (TFs) have been associated with 
CAD/MI, some of which have been discussed above. These include the GATA2112, myocyte-
specific enhancer factor 2A (MEF2A)113-115, proteasome subunit alpha 6 (PSMA6)116,117, 
transcription factor 7-like 2 (TCF7L2) genes, among others. GATA-2 constitutes a target gene 
ensemble consisting of genes encoding key determinants of endothelial cell identity and 
inflammation. These sites characteristically contained motifs that bind activator protein-1 
(AP-1), a pivotal regulator of inflammatory genes118. It plays an essential role in the 
establishment and maintenance of adult hematopoiesis, and is present in hematopoietic 
stem cells, as well as cells that make up the aortic vasculature, such as the aortic endothelial 
and smooth muscle cells. Several of the GATA2 gene variants have been associated with 
familial early onset of CAD112. The MEF2 is a member of the MADS gene family (name for 
the yeast mating type-specific transcription factor MCM1, the plant homeotic genes 
'agamous' and 'deficiens' and the human serum response factor SRF, a family that also 
includes several homeotic genes and other transcription factors, all of which share a 
conserved DNA-binding domain). This proteasome is a multicatalytic proteinase complex 
distributed throughout eukaryotic cells at a high concentration, and cleaves peptides in an 
ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a 
modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. 
Interestingly, a great majority of entities associated with disease reside in the untranslated 
regions (UTRs), particularly the 3 prime (3’-UTR) of these genes. Thus, for example, the 
MEF2A gene is highly polymorphic and harbours several deletions in the 3’-UTR that are 
implicated in CAD/MI113. The 3’-UTR regions contain sequences involved in gene 
regulatory and mRNA maturation processes. It also harbours binding sites for micro RNAs, 
which are involved in transcriptional and protein processing mechanisms. While the exact 
mechanisms are still to be elucidated, it appears nonetheless that changes in transcription 
factors, gene regulatory and mRNA maturation mechanisms exert important influence 
impacting disease pathways of complex diseases, such as CAD. Hence, the speculation that 
the disease-causing loci are more likely to be in DNA regions that regulate transcription 
rather than being in coding regions for protein119. Besides, novel genes also continue to be 
uncovered through genome-wide studies which do not belong to the canonical pathways of 
CAD, lipid metabolism or any of its other risk factors.   
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3.6 Gene-gene and gene-environmental interaction in manifestation of coronary artery 
disease 
The fact that several pathways commonly lead to CAD points to the possibility of 
interactions of these risk factors at various levels in the path to disease manifestation. 
Besides, the exceedingly high prevalence of risk factors such as T2DM, dyslipidaemia and 
hypertension in CAD individuals raises the question as to which pathway(s) or mechanism 
may be the primary cause of disease in cases harbouring combinations of such factors.  
This is compounded by the fact that, for example, the set of metabolic and physiologic  
risk factors associated with elevated cardiovascular disease risk including 
hypertriglyceridaemia, low HDL-C levels, hypertension, abdominal obesity, and insulin 
resistance all contribute to similar ailments, each of which may underlie genetic factors. The 
expression of each one of the major factors is now known to be the result of complex 
interactions between genetic and environmental factors. For example, as discussed above, 
obesity may play a major role in triggering the metabolic syndrome by interacting with 
variants in candidate genes for dyslipidaemia, hypertension and insulin resistance.  
Not surprisingly, in the last decade, a sizeable portion of research interest has focussed on 
trying to understand possible interactions among individual disease-causing variants or 
genes on complex disease manifestation. One of the most well studied systems is the RAAS 
pathway, which has been evaluated with respect to interactions among its risk 
variants/genes as well as with other genes in triggering CAD. Significant two-way and 
three-way gene-gene interactions between ACE I/D, AT1R A1166C polymorphisms and 
AGT gene haplotypes have been associated with CAD in a number of studies120. One study 
has described several synergistic effects between the studied polymorphisms and classical 
risk factors such as hypertension, obesity, diabetes and dyslipidaemia121. Thus, the presence 
of the DD genotype of ACE I/D (and also ACE11860 GG) increased the odds of developing 
CAD when related to each one of these classical risk factors, particularly in the male and 
early onset CAD subgroup analysis. Interactions have also been observed between ACE DD 
or ACE 8 GG with PON1 192RR in increasing the risk of CAD122,123. Concomitant presence of 
ACE DD and AT1R 1166 CC genotypes has also been reported to synergistically increase the 
predisposition to diastolic heart failure126. Significant interaction between APOE and LPL 
variants and HDL-C levels was also reported130, furnishing support to the idea that several 
polymorphisms in apolipoprotein genes may by themselves and/or in interaction with 
other polymorphisms contribute to risk for CAD in men130. Interaction of the GNB3 825T 
allele with the ACE D allele was also reported in MI131. 
Apart from the RAAS system, interactions have also been evaluated involving multiple gene 
variants with respect to CAD manifestation. One such a study linked increased risk of the 
disease in association with changes in genes belonging to different enzymes compared to 
the isolated polymorphisms122. Another study suggested that several polymorphisms in 
apolipoprotein genes may by themselves and/or in interaction with for example the PPARǄ 
C161-->T variant and apo ε4 genotype influence serum Chol level, in which the impact of 
the later on CAD was attenuated through the former genotype125. Epistatic, high-order, 
gene-gene interactions between RAS gene polymorphisms and CAD has also been 
discussed127. Similar interaction between variations in the ACE and ATR2 genes has been 
hypothesized in relation to the extent of coronary atherosclerosis129. 
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Other studies have addressed the possible interactions of various gene variants with risk 
diseases, such as hypertension or T2DM in acquiring CAD. For example, the AGT235 TT 
increased the CAD risk in the presence of hypertension and dyslipidaemia, while AT1R1166 
interacted positively with hypertension, smoking and obesity121. An interaction between 
RAAS predisposing genes and some biochemical/environmental risk factors was also 
reported in CAD onset, pointing to a significant enhancement of the effects of classical 
markers especially by ACE I/D and ACE11860121.  
One form of interaction currently attracting great attention is that of the haplotypes versus 
individual risk variants. Such an interaction would involve nucleotide changes occurring in 
the same genomic region, either within a single gene or in several genes at the same locus. 
Generally, it can be acknowledged that in many cases, haplotyping has been found to be 
more meaningful than individual variants. One study involving methylenetetrahydrofolate 
reductase C677T, plasminogen activator inhibitor 4G/5G, and endothelial nitric oxide 
synthase 3-27 base pair repeat polymorphism in patients with early-onset CAD suggested 
the coexistence of high-risk alleles as augmenting the severity of the disease128. These results 
are a manifestation of the relevance of the concept of multilocus and multi-gene effects in 
complex diseases, such as CAD.  
Besides, a number of genes are linked with changes in environmental factors affecting 
disease outcome. Thus, variables such as the postprandial lipid response have been shown 
to be modified by polymorphisms within multiple genes for the apolipoproteins, LPL, HL, 
fatty acid binding and transport proteins, MTP and scavenger receptor class B type I132, 
while several other genes including the apo A1/C3/A4/A5 cluster, ABCA1, CETP, human 
glucokinase regulatory protein (GCKR), HL, IL-6, LPL, lipid-droplet associated protein, 
perilipin, and TCF7L2 have all been implicated in the modulation of the postprandial lipid 
metabolism133. All these genetic changes in combination with other disease-causing 
elements are likely to exacerbate CAD. Furthermore, it has been suggested that the interplay 
of genetic and environmental factors places first-degree relatives of individuals with 
premature CAD at greater risk of developing the disease than the general population. 
However, the data on this subject is still very limited. Besides, reliability of available data on 
these interactions is not established, since replication studies are still lacking in the 
literature.  
4. Genetics of acute coronary syndrome in the young 
Acute myocardial infarction AMI in young individuals presents a typical pattern of risk 
factors, clinical, angiographic and prognostic characteristics that differ from those related to 
adult disease manifestation. An important feature of early onset is a positive family history, 
which has become a recognized cardiovascular risk factor. Cutaneous and tendinous 
xanthomata develop in childhood and are the most common reason for initial presentation. 
However, the pathogenic mechanisms are multifarious and complex. The frequency of FH is 
estimated to be 1 in 500. About 50% of individuals with FH die before the age of 60 due  
to MI.  
Since CAD manifests itself both as an early and late onset event, different risk factors may 
determine the stages at which the disease becomes apparent. A most useful approach for 
identifying genes associated with the condition involves linkage studies, which provide 
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leads through potential genomic loci that can be mined for candidate genes. A wealth of 
data pointing to several genomic links for ACS at a young age has already been produced in 
different laboratories. Examples include linkage to the 2q36-q37.3, 3q26-q27 and 20q11-
q13134, for which a number of gene are currently being targetted for further investigation. 
Among the suspect genes described thus far is the insulin receptor substrate-1 gene, thought 
to present a locus for combined disease processes of atherosclerosis, plaque instability, and 
coronary thrombosis134.  
 The natural link between familial dyslipidaemic disorders and early onset of CAD has 
placed genes involved in lipid metabolism at the focus of research interest. These studies 
have led to the discovery of several polymorphisms in the Apo B, LDLR and PCSK9 genes 
among others. Missense mutations in the LDLR-binding domain of Apo B are believed to 
cause familial ligand-defective Apo B, characterized by hypercholesterolemia and 
premature CAD. Heterozygosity of the LDLR is relatively common, and gain-of-function 
mutations in PCSK9 also cause autosomal dominant hypercholesterolemia, through 
elevation of plasma Chol concentrations associated with low-density lipoproteins (LDLs). 
Other gene polymorphisms involved in the increase in LDL include those in the Apo B, Apo 
E and LPL genes. The Apo ε4 has also been linked to an increased risk of AMI as well as 
independent predictor of adverse events at young age135. Familial LPL deficiency is a rare 
inborn error of metabolism caused by mutational changes within the LPL gene, leading to 
massive hypertriglyceridemia and reduced HDL-C, both of which are risk factors for the 
development of CAD. Besides, human HL deficiency as a second causative factor for 
hyperlipidaemia is also strongly associated with premature CAD43.  
Apart from the regulation of lipid metabolism, several other genetic variants have surfaced 
as risk for AMI in the last decade. Cross-sectional studies endeavouring to identify variants 
in candidate genes for early development of CAD and AMI have focused primarily on 
polymorphisms influencing certain biological functions, such as coagulation and 
fibrinolysis, platelets, vascular function, lipid metabolism and inflammation. Indeed various 
genes have been identified encoding coagulation proteins, fibrinolytic proteins, platelet 
receptors, homocysteine metabolizer, and those related to endothelial dysfunction, 
abnormal blood flow and oxidative stress136. Examples include genes encoding the 
prothrombin, apo E, Factor V Leiden, Factor VII, and transforming growth factor-ǃ1 (TGF-
ǃ1) genes137. Limited and controversial data also exists on the impact of the plasminogen 
activator inhibitor-1 (PAI-1) gene polymorphism in the pathogenesis of AMI. Thereby, some 
studies suggest that young patients <35 years possessing the 4G allele exhibit higher PAI-1 
plasma levels but lower Lp(a) levels compared to 5G/5G homozygotes, indicating that the 
4G allele of the PAI-1 4G/5G polymorphism is less frequent among survivors of MI at very 
young age compared with matched controls138. It has further been argued that AMI at 
young age could be also caused by a reduction of the fibrinolytic activity, in the presence of 
the PAI 4G allele.  
Because ischemic stroke with arterial occlusion or undetermined etiology is more likely to 
be related to a genetic prothrombotic state, polymorphic changes in genes regulating 
clotting processes have attracted attention as potential culprits of ACS. Thus, the platelet 
membrane receptor glycoproteins (GPs) are essential for the platelet activation process, and 
the genetic polymorphisms in the encoding genes may influence the risk of ACS and 
atherosclerosis. Recently, a metaanalysis implicated platelet glycoprotein IIb/IIa (GPIIb-
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IIIa), a membrane receptor for fibrinogen and von Willebrand factor and thrombopoetin 
variants in AMI98. The GP IIIa PI A2 allele has also been strongly associated with a previous 
history of MI, as well as the severity of disease, while in young smokers, the PAI-1 4G allele 
appears to present a mild risk factor for the development of MI139. Other gene variants 
including the GPIIb W86R mutation which produces a nonfunctional enzyme associated 
with elevated TG levels in the affected individual140, and the prothrombin G20210A variant 
which displayed a modest but significant risk factor for AMI at young ages141 have also been 
associated with the syndrome. An important aspect of the impact of these risk genes on  
ACS is the influence of the environmental components such as smoking, gender and 
socioeconomical factors. An example is the suggestion that the impact of the dominant mode 
for the thrombomodulin -33G/A polymorphism (GA+AA genotype) on a combination of 
CAD risk factors such as MI, hypertension and T2DM may be related to smoking in young 
individuals142 143. Thrombomodulin is an endothelial cell surface receptor for thrombin, 
which plays an important role in the regulation of blood coagulation by decreasing 
thrombin activity and activating protein C. A case study also reported an association of the 
Apo E (p.Arg136Cys) mutation and obese gene carriers, but with no severe dyslipidaemia in 
young smokers144. Also, synergistic effect of the MMP-3 5A/6A variant in the promoter 
region with smoking on the onset of AMI has been described in young patients with MI145. 
Furthermore, the contribution of the activated protein C resistance (APCR) as an increased 
risk for AMI has been described specifically in women smokers. 
Other studies also point to the metafolin folate (methyl tetrahydrofolate; MTHF), CD14, E-
selectin, eNOS and the PECAM1 genes as potential candidates for ACS98. Apart from being 
implicated in the onset of CAD, the MTHF C677T variant has been associated with the risk 
for recurrent coronary events. Elevated plasma homocysteine level at admission is 
considered to be an independent risk factor for these events after the first episode of ACS in 
young patients, irrespective of the status of this variant146. Interestingly, while an increased 
risk of developing coronary artery lesions was described in the presence of a mannose-
binding lectin (MBL2) variant in pediatric patients, in patients older than one year, an 
increased risk of the lesions was observed in wild-type genotype carriers, leading to the 
suggestion that MBL has an ambiguous role in Kawasaki disease and contributes differently 
to the pathophysiologic development CAD147. Another gene variant, the annexin V -1C/T 
seems to have a minor effect in bleeding disorders, but to play a protective role against AMI, 
reducing the risk of developing the disease148. 
Apart from genes regulating lipid metabolism and coagulation pathways, other gene 
families of importance in ACS include those encoding growth factors, proteins for 
proinflammatory processes, dyslipidaemia and obesity-related genes. These include two 
TGF-ǃ1 variants that have been linked AMI in young patients149. Associations between 
obesity-related variants, metabolic syndrome and AMI include those of ADIPO Q, LEPR 
MC4R and FTO polymorphisms. Furthermore, in a couple of case-control studies, Cx37 was 
implicated in AMI97. Also, a case-control study involving young patients with a first event of 
acute CAD or ischemic stroke, suggested that common variants in the VWF gene were 
associated with VWF levels and the risk for cardiovascular disease150. However, information 
on the contribution of common VWF gene variants to VWF levels and cardiovascular 
disease risk is still limited.  
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Plaque rupture is a well established critical factor in the pathogenesis of AMI. Recently, 
interest has also focussed on the relationship between inflammation and manifestation of 
atherosclerosis, leading to the identification of stromelysin-1 (i.e. matrix metalloproteinase-
3; MMP-3) as a risk gene. MMP-3 can degrade extracellular matrix and has been identified 
extensively in human coronary atherosclerotic plaques. It may contribute to the weakening 
of the cap and subsequent plaque rupture. Also, the aldosterone synthase (CYP11B2) -344 
C/T gene variant, which may influence plasma aldosterone levels, has been reported to 
strongly influence left ventricular diameters and mass in young adults and arterial stiffness 
in essential hypertensives. 
However, since CAD is a multifactorial disease, single mutations are likely to provide a 
small or modest contribution to risk, which may depend on interaction with other genes 
and/or a particular environment. Besides, there is still some controversy or uncertainties 
with regards to the role of some individual pathways or gene variants in ACS, such as those 
encoding some of the obese-related or RAAS genes90. For example, a borderline association 
for AMI with the ACE D/I polymorphism was described as a risk only in the occurrence 
and the long-term prognosis of AMI at young age in one study151, leading to the conclusion 
that polymorphisms in RAAS genes may be important in the onset of a first AMI in young 
patients, but not in the disease progression after a long follow-up period151. Besides, the role 
of some of the genes/ gene variants has been refuted by a number of studies. This includes 
the role of Factor V Leiden, where some studies reported protective effects of certain 
variants initially thought to be causative. A metaanalysis also refuted the association 
between the PlA1/A2 of the GP IIIa gene and young AMI, which had been implicated in a 
number of studies. The prothrombotic gene polymorphisms did not appear to have a 
significant influence on the prognosis in young ischemic stroke due to arterial occlusion of 
undetermined causes in a Taiwanese study152. However, these facts only stress the 
importance of replication of studies especially those that involve small numbers. More 
importantly, they reveal the importance of environmental factors especially for complex 
diseases such as CAD. Furthermore, this scenario points to the fact that not everything is 
known yet about the gene/gene variant responsible for CAD and its risk factors. Identifying 
such genes should greatly enhance our understanding of the intricacy of CAD 
manifestation, to identify individuals at risk and more importantly facilitate the 
development of more efficacious treatment strategies and introduction of early preventive 
measures. Thus, research efforts continue to address the identification of acquired and 
inherited risk factors of this complex disease. 
5. Genetics and drug therapy of coronary artery disease  
Treatment of coronary artery disease entails among others, lowering of circulating 
cholesterol, antiplatelet therapy representing the basis of treatment for the short- and long-
term prevention of atherothrombotic disease processes, as well as measures to prevent or 
treat hypertension, heart failure and T2DM. Factors involved in inflammation (cytokines, 
TNF), proliferation of smooth muscle cells and vasoactivation are also important. In all these 
incidences however, it is well established that patients often respond differently to drug 
therapy. For example, in the treatment of lipidaemic disorders, not all patients respond 
equally well to therapy with statins. There are several reasons why patients respond in 
different fashions to drug therapy. One major explanation is the mode by which the drugs 
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are metabolized by the various enzymes. It is now well recognized that genetic variations 
can contribute to these differences in drug disposition and, consequently, clinical efficacy at 
the population level. Thus, the metabolism may occur too rapidly, thereby leading to 
accelerated elimination from the body before it has had enough time to exert its effect. The 
opposite may equally be true that the drug is broken down too slowly resulting in its 
accumulation and therefore toxicity. Furthermore, the ability of the drug to bind to its 
receptor site may be hampered by changes in functional motifs of the target protein. 
Moreover, the level of the signalling message may be influenced by changes in the amount 
of target protein produced in different patients. All these factors could be due to sequence 
variations in human genes. 
With respect to cardiovascular disease per se, statins are probably the most frequently 
prescribed class of drug, and understandably great effort has been invested in trying to 
understand the genetics of variations in patient response as well as toxicity of these drugs. 
To begin with, the fact that considerable interindividual variation exists in response to statin 
therapy, in terms of both lipid-lowering and adverse drug reactions has been demonstrated 
in several candidate gene studies as well as meta-analyses from several primary and 
secondary intervention studies. Notably, most statins are the substrates of several 
cytochrome P450s (CYPs), and polymorphisms in these enzymes appear to be responsible 
for variations in their hypolipidemic activity. Strong association of sequence variants of 
several genes including HMGCR, CETP, SREBF1 and ABCG8 genes with the alteration in 
LDL-C reduction capability of different statins appears to be well-established153. Besides, 
drugs such as pravastatin and rotuvastatin are not susceptible to CYP inhibition, but are 
substrates of the a hepatic transporter and solute organic anion-transporting polypeptide 
(OATP) 1B1 (encoded by the SLCO1B1 gene) which is responsible for liver transportation of 
the statins154. Variants of the apolipoprotein, particularly the apo E and apo A5 also have 
their share in these processes155-158. Similarly, genetically impaired ABCG2 transporter efflux 
activity results in a marked increase in systemic exposure to various statins159. Importantly, 
the effects of these genetic polymorphisms differ depending on the specific statin that is 
used. With respect to reduction of MI though the use of statin, defective interaction may 
occur with a number of variants in several genes including the scavenger receptor class B 
member 1 (SCARB1) HMGCR, SREBF1, ABCG5/8, PCSK9, hepatic triglyceride lipase (LIPC), 
ABCA1, PPAR, LDLR-related protein 1 (LRP1) and SOAT1160 161 162. Other important features 
of statin pharmacokinetics include calmin gene polymorphism, which may exhibit 
differences on the actions of simvastatin, pravastatin and artovastatin on total and LDL-C 
reduction163 and ABCG2 which is associated with significantly greater LDL-C reduction 
with rosuvastatin compared to other statins 164.  
Furthermore, despite the high efficacy and almost universal use of statins in cardiovascular 
disease prevention, their adverse actions appear to be their greatest disadvantage. In this 
regard, the use of high dose of statins in combination with other drugs is also not without 
problems, since their pharmacokinetics may be altered, leading to increasing blood levels 
with consequent risk of liver or muscle toxicity as demonstrated most commonly for agents 
metabolized by the CYP450 3A4 enzyme. Specifically, simvastatin has been associated with 
an increased risk of rhabdomyolysis when taken in combination with multiple inhibitors of 
CYP3A4161. Moreover, while the safety data for the statins suggest a very low incidence of 
severe adverse reactions, such as rhabdomyolysis and myopathy, myalgias without serum 
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creatine kinase elevation remains a common side effect and the important reason for 
discontinuation of therapy. Myopathy has been reported in a considerable number of 
patients, but the mechanisms underlying muscle injury have yet to be fully characterized. 
These mechanisms may include statin-induced differences in Chol:phospholipid ratio, 
isoprenoid levels, small GTP binding proteins and apoptosis165. Furthermore, while 
depletion of Chol within the myocyte cell wall and/or the depletion of key intermediates 
within its synthesis pathway are hypothesized as possible mechanisms of statin-associated 
adverse drug actions (ADRs), pharmacogenetic variability may also contribute as a risk for 
ADRs155. These may include, for example, enzymes, transporters, cell membrane receptors, 
intracellular receptors or components of ion channels that contribute to the 
pharmacokinetics or pharmacodynamics of response to a particular drug. One of the genes 
identified thus far as likely to contribute to the development of simvastatin-induced 
myopathy and myalgia is the SLCO1B1 gene161,166. Thereby, the SLCO1B variant increases 
the risk of statin-induced myopathy by reducing the hepatic uptake of the statins. 
Essentially all statins are, in fact, substrates of membrane transporters, whereby SLCO1B1 
polymorphisms can decrease the liver uptake, as well as the therapeutic potential of these 
agents, and may be linked to their muscular side-effects. Elevated levels of simvastatin 
metabolites (but not pravastatin) have been observed among carriers of SLCO1B1*5 allele, 
pointing to a genetic susceptibility to both myopathy and statin-induced myalgias in the 
absence of elevated serum creatinine kinase167. The risk of myalgia among SLCO1B1 carriers 
appears to be unique for artovastatin. Also, polymorphic changes in the CYPs, CYP2D6, 
CYP3A4 and CYP3A5 are linked with statin-induced myopathy and show variable effects on 
altering the pharmacokinetic profile of statin metabolism. Furthermore, although myalgia 
appears to be associated with the whole group of drugs, there is a significant amount of 
variability within the class168 169.  
The major site of statin action is within hepatocytes and recent interest has also focussed on 
seeking the explanation for the differences in the impact of genetic variations in hepatic  
influx and efflux transporters170. Among the most promising candidate genes for 
pharmacogenomic analysis of statin therapy is the HMGCR as a direct target gene and other 
genes modulating lipid and lipoprotein homeostasis such as PPARs. A synergist effect has 
also been reported in which attenuation in lipid-lowering response to simvastatin caused by 
some LDLR haplotypes was enhanced in the presence of HMGCR haplotypes171, pointing to 
modulation of effects through gene-gene interactions.  
Apart from statin therapy, antiplatelet therapy represents the basis of treatment for the 
short- and long-term prevention of atherothrombotic disease processes, in particular in 
high-risk settings such as in patients with ACS and those undergoing percutaneous 
coronary intervention. Currently, the most common treatment involves dual antiplatelet 
therapy with aspirin and clopidogrel. Specifically, clopidogrel is a prodrug that undergoes 
hepatic biotransformation by CYP2C19 into its active metabolite. However, a considerable 
number of patients continue to experience adverse outcomes, including both bleeding and 
recurrent ischemic events, possibly attributable, in part at least, to the broad variability in 
individual response profiles to this standard antiplatelet treatment regimen172. Gene 
polymorphisms affecting clopidogrel metabolic bioactivation and platelet function may be 
responsible. These include CYP2C19 *2, *3 and *17, CYP2C9 *2 and *3, MDR1*2, and 
functional variants in the genes encoding platelet membrane receptors and intracellular 
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signaling proteins173,174. Moreover, gene polymorphisms may also have an important role in 
determining levels of platelet inhibition and provide a tool for identifying patients at risk of 
adverse events.  
In ischemic heart disease, the most commonly suspected genes are those related to lipid 
metabolism, coagulation and fibrinolytic systems as well as the RAAS pathway. Drugs that 
modulate the RAAS play an important role in advanced cardiovascular disease prevention 
strategies. Inhibitors of the RAAS, in particular ACE inhibitors are beneficial in specific 
patient groups, including those with hypertension, heart failure, diabetes mellitus and stable 
CAD. Hence ACE inhibitors are among the most commonly used drugs in stable CAD since 
they have been proven to be effective for reducing the risk of cardiovascular morbidity and 
mortality. However, while clinical trials demonstrated some consistent beneficial effect of 
ACE inhibitors across groups of patients based on clinical characteristics, the variability in 
treatment response on the individual patient level is high. Just as in the treatment of 
lipidaemic disorders, a primary cause seems to be genetic variations. Furthermore, 
treatment of diabetes constitutes an integral part of regimens to control coronary vascular 
disorders, which is similarly subject to issues of differences in patient responses to therapy. 
Examples include the uncoupling protein variant which has been correlated with ǃ-blocker 
response among ACS patients with diabetes175, and the SLCO1B1 gene variants also thought 
to be responsible for intolerance in diabetic patients176. Variability within the SLCO1B1 and 
ABCB1 genes are also linked with the modification of the effectiveness of statins in the 
prevention of the clinical outcome of MI177.  
However, while a great deal has been written about the potential of pharmacogenetic testing 
to informed therapy based on an individual's genetic makeup, and to decide the most 
effective choice of available drugs, or to avoid dangerous side effects, currently, there is little 
hard data for either in the field of cardiovascular disease. The usual approach has been the 
opportunistic use of drug trials in unrelated patients, and to look for differences in response 
or outcome by candidate gene genotype, for example, in those encoding drug metabolizing 
enzymes (activators and metabolizers), as well as enzymes and receptors involved in lipid 
metabolism, adrenergic response, among others. As with all association studies, initially 
promising results have often failed the test of replication in larger studies. An example is the 
attempt to employ relationship between the CETPTaq-I variant and response to statins, 
which has been ultimately withdrawn178. Nonetheless, ongoing exploration of genetic 
polymorphisms that influence response to drug therapy may one day allow the clinician to 
customize treatment strategies for patients in order to improve their success rate. In the 
treatment of CAD or ACS, greatest chance appears to have been accomplished in the area of 
regulating circulating lipids. The hope is that pharmacogenomic testing in future will allow 
risk stratification of patients to avoid serious side effects and enable clinicians to select lipid-
lowering drugs with the highest efficacy resulting in the best response to therapy. The 
compounds include drugs indicated for dyslipidaemia, such as statins, fibrates, niacin and 
cholestyramine, as well as those used for other purposes, including calcium channel 
blockers, angiotensin receptor blockers and glitazones. Furthermore, currently available 
data from pharmacogenetic trials, a combined analysis of multiple genetic variants in 
several genes is more likely to give significant results than single gene studies in small 
cohorts. Thus, larger studies or combination analyses involving more than two different 
polymorphisms would enable us to find clinically or biologically more meaningful 
differences, and genes influencing Chol biosynthesis in the liver, such as ABCG5/G8, 
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CYP7A1, HMGCR, would be good candidates. In this regard, plasma TG concentration is 
also reemerging as an important cardiovascular disease risk factor. More complete 
understanding of the genes and variants that modulate plasma TG should enable 
development of markers for risk prediction, diagnosis, prognosis, and response to therapies 
and might help specify new directions for therapeutic interventions. 
6. Summary  
Atherosclerosis is a multifactorial, multistep disease that involves chronic inflammation at 
every step, from initiation to progression, and all the risk factors contribute to pathogenesis 
by aggravating the underlying inflammatory process. Despite well-invested efforts to 
minimize attributable risk from known contributors to the disease such as hypertension, 
dyslipidaemia, and smoking, CAD remains the number one cause of death in industrialized 
countries. Clinical trials have consistently demonstrated a family history of coronary disease 
to be predictive for future cardiovascular events beyond that which would be explained by 
traditional risk factors. These findings do not only support but also have prompted great 
interest to study the genomic basis of CAD and MI. Recent advances in genotyping 
technology have allowed for easier identification and confirmation of susceptibility genes 
for complex traits across different cohorts in the pathways leading to CAD. This has been 
facilitated through increased power of studies enhanced by faster accrual of cases and 
control subjects and more precise genetic mapping, and have allowed us define the genes 
contributing to a possibly great majority of population-attributable risk for T2DM, 
hypertension and ACS. Similar progress in replicating novel susceptibility genes for CAD 
and specifically MI is now advancing rapidly. Several genes have already been identified 
and more are in the pipeline. With improved resequencing technology and better 
phenotypic characterization of the CAD cases and control subjects, comprehensive 
identification and confirmation of genes associated with CAD risk appear to be around the 
corner, in order to allow us to better quantify CAD risk early enough in life and institute 
more effective therapy reducing the burden of an individual developing CAD. However, 
being a complex disease, the disease pathways to CAD are interwound in an intricate 
network, which together with environmental factors require complex tools to decipher. Such 
an in-depth knowledge of the various pathogenic mechanisms involved in the disease will 
significantly enhance our substantiation of the existing knowledge about the disease.  
Furthermore, while substantial progress has been made in the identification of  
common DNA sequence variations in genes influencing the pharmacokinetics and 
pharmacodynamics of related drugs and in disease-modifying genes relevant for CAD, our 
present understanding of pathophysiological mechanisms does not offer a reliable approach 
to address the same at preclinical level. Pharmacogenomics can provide important insights 
into the therapy of CAD and related risk factors through elucidation of the genetic (or 
genomic) contribution to variable response to different drugs. The search for genetic 
polymorphisms may enable us to identify novel determinants of drug responsiveness by 
studying candidate gene belonging to the gene families that encode proteins involved in 
pharmacokinetics, the genes encoding proteins engaged pharmacodynamics and genes 
encoding proteins involved in the underlying disease condition or intermediate phenotype. 
A better understanding of the pathogenesis of CAD will enhance the advancement of 
pharmaceutical and lifestyle modifications for reducing mortality resulting from the disease. 
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